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Abstract 
Because of their potent antigen-presenting capacity, dendritic ceils (DC) have been used 
extensively in immunotherapy protocols. Our purpose was to functionally characterize mouse bone 
marrow-derived DC (BMDC) in vitro (in protein antigen- and hapten-specific assays) and in vivo 
(injecting soluble protein- and hapten-pulsed DC) to determine their suitability for the generation of 
Th cell responses. Furthermore, we determined whether there is cross-presentation on MHC class II 
molecules during in vivo protein and hapten sensitization. Co-culture of protein-pulsed [with hen 
egg lysozyme (HEL) or with pigeon cytochrome c (CYT)] DC with T cells from HEL- or CYT-
sensitized mice induced antigen-specific T cell proliferation, but compared to cultured Langerhans 
cells (LC), BMDC required higher protein antigen-pulsing concentrations (100 pg and 1 mg/ml). In 
contrast, at low protein concentrations (10 pg/ml), BMDC stimulated an HEL-specific hybridoma 
very efficiently. Using an in vitro T cell proliferation assay and in vivo delayed-type hypersensitivity 
and contact sensitivity assays, we found that protein- and hapten-pulsed BMDC were able to 
sensitize syngeneic but not allogeneic hosts. Furthermore, if we injected BALB/c- and C57BL/6-
derived HEL-pulsed BMDC into F, mice, specific secondary proliferation of primed T cells occurred 
only when antigen-pulsed stimulator cells syngeneic to the injected BMDC were used. Using this 
model system we found that soluble proteins and haptens are presented by injected BMDC to host 
T cells in an MHC-restricted manner in vivo. 
Introduction 
Dendritic cells (DC) are highly efficient antigen-presenting 
cells (APC) that capture, process and present antigens to 
naive and primed T cells (1,2). Their ability to initiate potent T 
cell responses in vivo without any adjuvant has encouraged 
their utilization for immunization purposes. 
Recent studies have focused on the induction of cytotoxic T 
lymphocyte (CTL) responses with tumor or virus killing activity. 
In these studies the authors used (3-7) tumor extracts or tumor 
RNA (8) which induced antigen-specific CTL mediating tumor 
immunity. Human trials using DC loaded with tumor antigens 
have shown (9-11) promising results. However, using MHC 
class l-restricted pathways ignores the role of MHC class 
ll-restricted Th cells in initiating and sustaining immune 
responses. 
Thus, our first goal was to functionally characterize bone 
marrow-derived cells (BMDC) to initiate CD4+ Th cell 
responses. We used the soluble proteins hen egg lysozyme 
(HEL) and pigeon cytochrome c (CYT) to study the charac-
teristics of MHC class ll-restricted presentation and immuni-
zation. The fate of injected DC is not fully known; furthermore, 
there Is very limited knowledge about the phenomenon of 
cross-presentation. It is known that during both the mainten-
ance of tolerance and the rejection of malignant cells and 
transplants there is a representation of antigens In association 
with MHC class I and II products. The mechanism of cross-
presentation of peptides presented on MHC class I molecules 
has recently been shown (12,13) to be transfer of peptide from 
apoptotic cells to DC. Sauters et al. found that DC phagocy-
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tose apoptotic and necrotic cell lines, but only the latter cause 
potent maturation of DC (14). In contrast of our knowledge 
about the cross-presentation of antigens on MHC class I 
molecules, much less is known about presentation of antigens 
on MHC class II molecules. Recently, Inaba etal., using a mAb 
that specifically recognizes complexes formed between an 
MHC class II molecule and a peptide, were able to detect the 
formation of MHC class ll-peptlde complexes in vitro and 
in vivo after phagocytosis of cell fragments (15). Using in vitro 
and in vivo functional assays we herein show that BMDC 
pulsed with Intact soluble proteins or haptens Induce CD4+ Th 
responses In an MHC-restrlcted manner. 
Methods 
Mice 
Female BALB/c (l-Ad), C57BL/6 (l-Ab) and F, (CB6/F,) mice 
aged 6-12 weeks old (Animal Production Area, National 
Institutes of Health, Frederick, MD) were used in all experi-
ments, and were housed under pathogen-free conditions. 
Cells 
BMDC were generated using the method of Fields et al. (10) 
with minor modifications. Briefly, BM was flushed from tibias 
and femurs of female BALB/c or C57BL/6 mice and depleted 
of red blood cells with ammonium chloride. Cells were plated 
at 1 x 10® cell/ml In T162 flasks in 50 ml DC medium [DCM: 
RPMI 1640 containing 5% FCS (Biofluids, Rockvllle, MD), 50 
p.M 2-mercaptoethanol (Sigma, StLouls, MO), 10 mM HEPES, 
pH 7.4, 2 mM glutamlne, 100 U/ml penicillin, 100 pg/ml 
streptomycin and 20 pg/ml gentamycin (all from Life 
Technologies, Chagrin Falls, OH), supplemented with 10 ng/ 
ml granulocyte macrophage colony stimulating factor (GM-
CSF) and 10 ng/ml IL-4 (PeproTech, Rocky Hill, NJ)]. On day 
5, cultures were fed with an additional 25 ml of DCM. On day 7, 
non-adherent and loosely adherent cells were harvested by 
vigorous pipetting of cultures. Harvested cells were resus-
pended In RPMI + 5% FCS and 10 mM HEPES at 5 x 10® cells/ 
ml. Then 10 ml aliquots of this cell suspension were layered 
onto 15 ml of 14.5% metrizamide (Sigma)/RPMI + 5% FCS and 
10 mM HEPES solution In a 50 ml centrifuge tube and 
centrifuged at 1700 g for 10 min at 4°C. The resulting cell 
interphase was harvested, washed twice in RPMI + 5% FCS 
and 10 mM HEPES, and subcultured in DCM for an additional 
1 day. On day 8. non-adherent cells were harvested and these 
cells are referred to as BMDC. The purity of BMDC as 
determined by FACS analysis was routinely 85-95%. 
Contaminating cells were mostly granulocytes and macro-
phages. No T or B cells were detected. 
Epidermal cells (EC) 
Single EC suspensions were obtained from ears of untreated 
BALB/c or C57BL/6 mice as previously described (16). Fresh 
LC were obtained by Lympholyte M (Cedarlane, Hornby, 
Ontario, Canada) gradient centrlfugation as previously de-
scribed (17) or further cultured (1.5 x 10® cells/ml) in RPMI 
1640 containing 10% FCS (Biofluids) [or, in some experiments, 
with 1.5% syngeneic mouse serum (sMS)], 50 pM 2-
mercaptoethanol (Sigma), 10 mM HEPES, pH 7.4, 2 mM 
glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin, 1% 
non-essential amino acids and 1 mM sodium pyruvate 
(cRPMI), which was supplemented with 10 ng/ml GM-CSF 
when sMS was used. After 48 h of culture (cLC), non-adherent 
EC were harvested by vigorous pipetting and LC were 
enriched by density gradient centrifugation (Lympholyte M). 
Interphase cells were washed extensively and stained with 
anti-l-A antibodies for FACS analysis to determine the per-
centage of LC (which was usually -5-10% when freshly 
trypsinlzed cells were used and 25-30% when cLC were 
used). These cells were used as APC In protein or contact 
sensitivity assays. 
T cell hybridoma 
The T cell hybridoma B9.1, specific for the immunodominant 
peptide HEL103-117 (18), was used to detect presentation of 
HEL by BMDC and LC, and was kindly provided by Dr J. 
Kanellopoulos (Laboratoire de Blologle Moleculaire du Gene, 
INSERM U277, Institute Pasteur, Paris, France). 
Flow cytometry 
Expression of surface molecules was quantified by flow 
cytometry using the following antibodies: CD4 (H129.19), 
CD8a (53-6.7), CD11b (M1-70), CD11c (HL3), CD14 (rmC5-3), 
CD16/32 (2.4G2), CD40 (3/23), CD45R/B220 (RA3-6B2), 
CD54 (3E2), CD80 (16-10A1), CD86 (GL-1), Gr-1 (RB6-8C5) 
l-Ad (AMS-32.1), l-Ab (AF6-120.1) and isotype controls, pur-
chased as purified, FITC- or phycoerythrin-conjugated mAb 
from PharMlngen (San Diego, CA). Anti-murine macrophage 
(F4/80) mAb were purchased from Serotec (Oxford, UK). 
Staining was performed according to standard techniques 
and cells were analyzed with a FACScan flow cytometer using 
CellQuest software (Becton Dickinson, Mountain View, CA). 
Dead cells were excluded from all analysis by propldlum 
Iodide (100 nM; Sigma) staining. 
In vitro protein antigen presentation assay 
To prime T cells with proteins, either 100 pg of HEL or 100 pg of 
the non-cross reacting protein pigeon CYT (both Sigma) were 
emulsified in complete Freund's adjuvant (1:1) and injected 
Into the left hind footpads of mice. After 7 days, popliteal lymph 
nodes were collected, pooled and CD4+ T cells were purified 
with a mouse CD4 subset column kit ( R & D Systems, 
Minneapolis, MN). In this and all of the other experiments, 
appropriate sMS was added to the media when T cells were 
purified for co-culture experiments in order to avoid T cell 
responses to FCS components. The resulting CD4+ T cell 
preparations contained <0.2% l-A+ cells. T cells were plated at 
2 x 10s cells/well In 96-well flat bottom microplates (Costar, 
Corning Inc., Corning, NJ) in cRPMI 1640 containing 1.5% 
heat-inactivated sMS and supplemented with 1 pg/ml indo-
methacln (Sigma), referred to as proliferation assay medium 
(PAM). BMDC cultures were fed on day 5 with DCM containing 
various concentrations of HEL or CYT. DC were purified by 
metrizamide gradient centrlfugation on day 7. The interphase 
cells were washed extensively and replated at 5 x 10s cell/ml 
in DCM. On day 8, cells were washed, ^-irradiated with 3000 
rad and added to T cells to achieve various stimulator:re-
sponder ratios. Freshly separated LC were enriched by 
gradient centrifugation and plated In 10 ml T flasks in complete 
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Fig. 1. Cell surface phenotype of BMDC harvested on day 8 
cultured with GM-CSF and IL-4. Cells were stained as described in 
Methods. Cells express high levels of MHC class II molecules, 
moderate to high levels of CD86, CD80 and CD54 co-stimulatory 
molecules, were positive for CD11c and CD11b, and negative for 
CD14. Few cells expressed F4/80 molecules. Shaded areas, mAb of 
interest; unshaded areas, isotype control mAb. Representative data 
from one of five experiments. 
RPMI containing various concentrations of HEL or CYT. After 
48 h of culture, cells were harvested, washed 3 times in HBSS/ 
1.5% sMS, ^-irradiated with 1500 rad and added to the T cells. 
On day 3 of co-culture, [3H]thymidine (Amersham, 
Biosciences Corp., Piscataway, NJ) (1 pCi/well) was added 
and T cell proliferation was determined by the incorporation of 
[3H]thymidine during the last 16 h of culture using a gas 
ionization counter (Packard, Meriden, CT). Results are pre-
sented as the mean (± SEM) of assays performed in 
triplicates. 
Presentation of protein to antigen-specific T cell hybridoma 
cells in vitro 
After incubation of BMDC or LC with HEL or CYT as described 
above, cells were added to 1 x 10s cells/well of B9.1 T cell 
hybridoma cells in 96-well flat-bottom microplates and 
cultured for 24 h at 37°C. One hundred microliters of culture 
supernatant was removed and assayed for IL-2 content using 
an ELISA assay ( R & D Systems). 
in vivo immunization with protein-pulsed BMDC 
BMDC were pulsed with 1 mg/ml HEL or CYT as described 
above. Day 8 cells were washed 3 times with HBSS, and 3-5 x 
105 antigen-pulsed and non-pulsed BMDC were injected into 
the left hind footpads of naive recipient mice. Seven days after 
immunization, draining popliteal iymph nodes were harvested 
and CD4+ T cells were purified as described above. The 
resulting T cell population contained <0.2 % MHC ll+ cells. For 
assessment of intensity of the T cell responses to the in vivo 
immunization, LC were puised as described above, y-iTadi-
ated with 1500 rad, graded numbers of LC were added to 2 x 
105 T cells/well and T cell proliferation was assessed as 
described above. In the cross-presentation experiments, 
allogenic HEL-pulsed or non-pulsed BMDC were prepared 
and injected as described above. In the proliferation assay LC 
syngeneic to the T cells were used as stimulators. The 
proliferation assays were performed in 1.5% sMS containing 
PAM. In the cross-presentation experiments using (BALB/c x 
C57BL/6) Ft mice as hosts, both BALB/c and C57BL/6-
derived LC were used as stimulators, and 1.5% Ft sMS was 
used in the stimulator assays. 
Delayed-type hypersensitivity (DTH) assay 
To sensitize for protein antigens, mice were injected s.c. at two 
sites in the lower abdomen either with 2-5 x 105 protein-
pulsed BMDC in 100 pi HBSS solution or, as a positive control, 
with 100 pi HEL/complete Freund's adjuvant. Non-pulsed 
BMDC and naive, non-sensitized animals served as negative 
controls. Challenge and measurement of ear thickness was 
performed as previously described (19). Each experimental 
group contained 10 mice. 
Hapten modification of cells 
Day 8 BMDC and cLC were TNP conjugated as previously 
described (17). Trypan blue exclusion revealed that 90% of 
cells were viable. 
Sensitization and elicitation of contact hypersensitivity 
Graded numbers (104-106 cells/mouse) of TNP-modified and 
unmodified BMDC and LC were injected in 100 pi HBSS/5% 
FCS s.c. into the dorsal trunk skin of BALB/c, C57/BL6 or F-, 
mice. As positive controls, mice were sensitized by epicuta-
neous application of 100 pi 3% trinitrochlorbenzene (TNCB; 
Polysciences, Warrington, PA) in acetone:olive oil (4:1) to the 
dry-shaved abdomen. As negative controls mice were painted 
with the vehicle alone on the abdomen. Challenge and 
measurement of ear thickness was performed as previously 
described (17). Experimental groups consisted of five mice 
each. One-way ANOVA was used to compare experimental 
and control groups. 
Presentation of TNBS by BMDC to TNCB-sensitized CD4+ 
cells in vitro 
Mice were painted with 100 pi of 3% TNCB as previously 
described (17). Brachial, axillary and inguinal lymph nodes 
were harvested 6 days later, and purified for CD4+ cells as 
described above and plated in 96-well plates at 2 x 10s cells 
in 100 pl/well. BMDC were conjugated with TNBS as previ-
ously described, washed extensively and added to wells in 
various numbers. Proliferation assays were performed as 
described above. 
Assessment of secondary responses of lymph node T cells 
sensitized by TNBS-conjugated BMDC 
BALB/c-derived BMDC were conjugated with TNBS as 
described above, washed extensively and resuspended in 
HBSS. TNBS-conjugated or non-conjugated BALB/c-derived 
BMDC (3-5 x 10s) were injected in 50 pi into the hind footpads 
of BALB/c and C57BL/6 mice. Draining popliteal lymph nodes 
were harvested 6 days later and purified for CD4+ cells as in 
the previous experiments. As stimulator cells, we used 
BALB/c- and C57BL/6-derived LC, which were cultured in 
1.5% sMS-containing medium for 2 days and conjugated with 
TNBS as described above for BMDC. MHC-matched stimu-
lators and responder cells were co-cultured in the appropriate 
sMS-containing PAM and proliferation assays were per-
formed. 
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Fig. 2. High concentration of protein is required to pulse BMDC in 
order to achieve significant antigen-specific proliferative response of 
primed T cells in vitro. BMDC were pulsed on day 5 of culture with 
various concentrations (100 |ig, 500 ng, 1 mg and 3 mg) of HEL 
(BMDC-HEL, closed symbols) or left non-pulsed (BMDC-NP, open 
symbol). Langerhans cells were pulsed with 100 ng HEL (LC-HEL) 
or left unpulsed (crossed symbols). On day 7, BMDC were purified 
by gradient centrifugation and subcultured overnight. Day 8 BMDC 
and 2-day cultured LC were washed extensively to remove excess 
antigen, irradiated and co-cultured with 2 x 105 CD4" T cells 
purified from draining popliteal lymph nodes 7 days after mice were 
injected with 100 pg HEL/complete Freund's adjuvant or with 100 pg 
CYT/complete Freund's adjuvant (hatched symbols) as negative 
control. The LC number was normalized by the percentage of class 
II" cells by flow cytometry in this and all other experiments. 
Proliferation assays were performed in 1.5% sMS-containing 
medium in this and all other experiments. When cultured alone, T 
cells [non-stimulated or staphylococcal enterotoxin B (10 pg/ml) 
stimulated] as well as irradiated stimulators did not proliferate. In 
this and all other experiments cell proliferation was measured on 
day 4 by counting 16 h incorporation of [3H]thymidine (mean ± SE 
in triplicate wells). Representative data from one of four similar 
experiments are shown. 
Results 
Cell surface phenotype of BMDC generated with GM-CSF 
and IL-4 
Day 8 BMDC cultured with GM-CSF/IL-4 supplemented 
media expressed high levels of MHC class II molecules, 
high levels of CD86, CD80 and CD54 co-stlmulatory 
molecules, and were positive for CD11c and CD11b, and 
negative for CD14 (Fig. 1). Few cells expressed F4/80 
molecules. Addition of Escherichia coli lipopolysaccharlde 
(100 ng/ml; provided by Dr Stephanie Vogel, Uniformed 
Services University of the Health Sciences, Bethesda, MD) 
or HEL (up to 3 mg/ml) or tumor necrosis factor-a (10 ng/ 
ml; R & D Systems) or antl-CD40 (HM40-3; 10 pg/ml 
PharMlngen) to 8-day gradient-purified BMDC for 2 days 
did not significantly enhance the surface expression of 
class II or co-stimulatory molecules (data not shown). 
These findings suggest that 8-day BMDC, which we used 
In all of our experiments, exhibited a highly mature 
phenotype. 
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Fig. 3. IL-2 production of the HEL-specific T cell hybrldoma B9.1 in 
response to antigen-pulsed BMDC. BMDC were pulsed with various 
concentrations (1 pg. 10 pg, 100 pg, 1 mg and 3 mg) of HEL 
(BMDC-HEL) or 3 mg CYT (BMDC-cyto) as described in Fig. 2, 
harvested on day 8 and washed extensively to remove excess 
antigen. Irradiated cells were added to 1 x 105 cells/well of B9.1 T 
cell hybridoma in 96-well flat-bottom microplates and cultured for 24 
h at 37°C. Aliquots of 100 pi of culture supernatant were removed 
and assayed for IL-2 content as a measure of antigen-specific T cell 
stimulation, using an IL-2 ELISA assay. T cells alone and irradiated 
BMDC alone did not produce measurable amounts of IL-2. One 
experiment representative of three is shown. 
BMDC process and present soluble protein antigens in 
association with MHC II molecules 
To assess the in vitro antigen-presenting capacity of BMDC, 
the cells were either left unpulsed or pulsed with different 
concentrations (0.1-3 mg/ml) of HEL or CYT and graded 
numbers of these cells were added to fixed numbers of HEL-
or CYT-prlmed T cells. BMDC pulsed with 0.1 mg/ml of protein 
Induced little (and in some experiments, no) proliferation of 
primed T cells. Only BMDC pulsed with high concentrations 
(0.5 < 1 « 3 mg/ml) of protein were able to regularly induce 
significant antigen-specific T cell proliferation (Fig. 2). In 
subsequent experiments, we used 1 mg/ml protein for pulsing 
because this concentration consistently induced significant T 
cell proliferation. 
Cultured LC process and present soluble protein antigens 
and induce enhanced secondary Th cell responses 
compared to BMDC 
When the antigen-presenting capacity of BMDC and LC were 
compared using different concentrations (0.1-3 mg/ml) of 
protein antigen, LC Induced highly specific T cell proliferation 
at lower protein-pulsing concentrations (0.1 mg/ml) (Fig. 2). If, 
however, higher concentrations were used, BMDC were as 
potent stimulators as LC, suggesting either that LC might 
capture or process antigen in a more efficient manner, or that 
LC express co-stlmulatory molecules that function more 
effectively than those expressed by BMDC. Although this 
comparison may not provide an important distinction between 
the two cell types because of the differences in Isolation 
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Fig. 4. Priming for soluble protein antigens occurs in an MHC-
restricted manner. Primary sensitization of BALB/c (A) and C57BL/6 
(B) mice was attempted by Injection of 3 -5 x 105 BALB/c BMDC 
that had been left unpulsed (open symbols) or were pulsed (closed 
symbols) with 1 mg/ml HEL as described in Fig. 2 or by injection 
with 100 j ig HEL in complete Freund's adjuvant (hatched symbols). 
Stimulator cells in the secondary response were unpulsed (squares) 
or pulsed (triangles) BALB/c- or C57BL/6-derived cultured LC, which 
were irradiated, washed extensively and plated in 96-well flat-bottom 
tissue culture plates in graded numbers with 2 x 105 purified 
BALB/c or C57BL/6 CD4+ lymph node T cells. T cells primed with 
s.c. injection of syngeneic HEL-pulsed BMDC proliferated in 
response to syngeneic HEL-pulsed LC, in contrast to T cells primed 
by allogeneic HEL-pulsed BMDC that did not proliferate. When 
cultured alone, T cells [non-stimulated or staphylococcal enterotoxin 
B (10 pg/ml) stimulated] as well as irradiated stimulators did not 
proliferate. One experiment representative of three Is shown. 
techniques and in culture conditions, the results indicate that 
the two cell types may differ in their ability to present antigen. 
Presentation of HEL to HEL-specific T cell hybridoma cells 
To evaluate the capacity of BMDC to present HEL to the HEL-
specific T cell hybridoma B9.1, BMDC were pulsed with 
different concentrations of HEL or CYT (as control antigen) 
and incubated with the hybridoma cells for 24 h. BMDC pulsed 
with as little as 10 p.g/ml HEL were able to induce specific T cell 
proliferation as determined by significant IL-2 production (Fig. 
3). This result probably reflects the fact that T cell hybridomas 
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Fig. 5. BMDC prime F, T cells In an MHC ll-restricted manner. (A) 
Primary sensitization of F, (BALB/c x C57BL/6) mice was attempted 
by injection of 3-5 x 105 BALB/c BMDC that had been left unpulsed 
(open symbols) or were pulsed (closed symbols) with 1 mg/ml HEL 
as described In Fig. 2. Stimulator cells in the secondary response 
were unpulsed (squares) or pulsed (diamonds) BALB/c-derived 
cultured LC and unpulsed (circles) and pulsed (triangles) C57BL/6-
derived cultured LC, which were irradiated, washed extensively and 
plated In 96-well flat-bottom tissue culture plates in graded numbers 
with 2 x 105 purified F-i CD4+ lymph node T cells. (B) Primary 
sensitization of F, mice was attempted by injection of 3 -5 x 10s 
C57BL/6 BMDC that had been left unpulsed (open symbols) or were 
pulsed (closed symbols) with 1 mg/ml HEL as described in Fig. 2. 
Stimulator cells In the secondary response were unpulsed (squares) 
or pulsed (diamonds) BALB/c-derived cultured LC and unpulsed 
(circles) or pulsed (triangles) C57BL/6-derlved LC, which were 
irradiated, washed extensively and plated as described in (A). HEL-
pulsed LC induced significant secondary proliferation of those F, T 
cells primed with syngeneic HEL-pulsed BMDC. In contrast, T cells 
primed by HEL-pulsed BMDC allogeneic for the stimulators did not 
proliferate. When cultured alone, T cells [non-stimulated or 
staphylococcal enterotoxin B (10 p.g/ml) stimulated] as well as 
Irradiated stimulators did not proliferate. One experiment 
representative of three is shown. 
require less anflgen-MHC class II complexes on the APC 
surface and little or no co-stimulation in order to secrete IL-2. 
Soluble antigen-pulsed BMDC prime lymph node T cells 
in vivo in an MHC-restricted manner 
After pulsing with 1 mg/ml of HEL or CYT, as described above, 
3-5 x 10s BALB/c-derived BMDC were injected Into the left 
hind footpad of BALB/c and C57BL/6 (l-Ad and l-Ab) mice. 
Draining popliteal lymph nodes were harvested, pooled, and 
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Fig. 6. DTH response of mice immunized with syngeneic or 
allogeneic HEL-pulsed BMDC. BALB/c- and C57BL/6-derived 
BMDC were pulsed with 1 mg/ml HEL (BMDC/BA-HEL and BMDC/ 
B6-HEL) as described in Fig. 2 or left unpulsed (BMDC/BA and 
BMDC/B6). Mice were injected s.c. at two sites in the lower 
abdominal skin either with 2 -5 x 105 cells in 100 pi HBSS solution or 
with 100 pi HEL/complete Freund's adjuvant (2 mg HEL/ml) as a 
positive control. Naive, non-sensitized animals served as negative 
controls. Six days later mice were challenged by injecting 25 pi of 
HEL in PBS (2 mg/ml) s.e. into the left footpad, whereas as a control 
25 pi of PBS was injected into the right footpad. After 24 h, footpad 
thickness was measured and the footpad-swelling response was 
calculated as the thickness of the left footpad minus the swelling of 
the right footpad. Only syngeneic HEL-pulsed BMDC were able to 
sensitize for a DTH response; neither non-pulsed nor HEL-pulsed 
allogeneic BMDC could prime for HEL. Data are representative of 
three independent experiments, showing the mean ± SEM (n - 10) 
of the footpad swelling response. *P < 0.05 and "P < 0.01 
assessed by one-way ANOVA. 
CD4+ T cells were purified and assessed for secondary 
responses to antigen-pulsed APC. As APC, HEL- or CYT-
pulsed cLC were used and added to the syngeneic purified 
lymph node T cells. Antigen-pulsed LC specifically stimulated 
those lymph node T cells primed with antigen-pulsed 
syngeneic BMDC, but not those primed with allogeneic 
BMDC (Fig. 4). This finding indicates that priming occurs in 
an MHC-restricted manner and, more importantly, shows that 
there is no cross-presentation by host APC. It excludes the 
possibility that there is representation of antigens by auto-
logous APC. To further investigate the phenomenon of cross-
presentation on MHCII molecules, we injected 3-5 x 105 HEL-
pulsed and non-pulsed BALB/c- and C57BL/6-derived BMDC 
into the footpad of F, (BALB/c x C57BL/6) mice, The draining 
lymph nodes were harvested 7 days later and CD4+ T cells 
were purified and assessed for secondary T cell responses as 
described above. Stimulator HEL-pulsed and non-pulsed LC 
from BALB/c and C57BL/6 mice were cultured for 2 days in 
sMS-containing medium, and the proliferation assay was 
performed in each condition in PAM supplemented with 1.5% 
1000 10000 
APC/well 
Fig. 7. In vitro proliferative response of TNCB-sensitized T cells to 
TNBS-conjugated BMDC and LC. Mice were painted on the shaved 
thorax and abdomen with 3% TNCB. Cervical, axillary and inguinal 
lymph nodes were harvested 6 days later, purified for CD4-1- T cells 
and 2 x 10s cells/well of these responder cells were plated in a 96-
well flat-bottom tissue culture plate. BMDC and 2-day cultured LC 
were conjugated with 1 mM TNBS for 10 min (BMDC-TNBS and LC-
TNBS), washed extensively, irradiated and plated to achieve various 
responder:stimulator ratios. Non-conjugated BMDC and LC served 
as negative controls. TNBS-conjugated BMDC induced a response 
similar in magnitude to TNBS-conjugated LC. When cultured alone, 
T cells [non-stimulated or staphylococcal enterotoxin B (10 pg/ml) 
stimulated] as well as irradiated stimulators did not proliferate. This 
experiment is representative of two independent experiments. 
serum obtained from Ft mice. BALB/c-derived HEL-pulsed 
stimulator LC could not induce secondary proliferation of T 
cells primed with HEL-pulsed C57BL/6 BMDC. In parallel, 
C57BL/6-derived HEL-pulsed LC did not induce secondary 
proliferation of T cells harvested from F, mice primed with 
BALB/c-derived HEL-pulsed DC (Fig. 5). These findings 
indicate that peptides presented in association with one of 
the MHC II type molecules could not induce clonal T cell 
expansion of T cells with TCR specific for the other MHC class 
II molecule. 
BMDC induce DTH in an MHC-restricted manner 
To further evaluate the immunogenic potential of protein-
pulsed BMDC in vivo we assessed the mice for expression of 
DTH. A single s.c. injection of HEL-pulsed BMDC (4-10 x 10s 
cells/mouse), but not unpulsed BMDC, led to successful 
immunization of both BALB/c and C57BL/6 mice. Next we 
injected HEL-pulsed BALB/c- and C57BL/6-derived BMDC 
into syngeneic or allogeneic hosts to assess whether allogenic 
BMDC were able to sensitize mice for HEL. Only when the 
injected cells were syngeneic to the recipient was a significant 
foot-swelling response detected. In contrast, if we injected 
allogeneic HEL-pulsed BMDC, no significant responses were 
detected (Fig. 6). This in vivo cross-priming experiment 
demonstrated that soluble antigen-pulsed BMDC cannot 
immunize allogeneic hosts for protein antigen-specific re-
sponses. 
Hapten-modified BMDC and hapten-modified LC induce 
comparable amounts of proliferation of antigen-specific T 
cells 
We next determined whether BMDC cultured in this way were 
able to present haptenated antigens in vitro. We sensitized the 
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Fig. 8. Injection of TNBS-conjugated BMDC induces contact 
sensitivity in vivo. BMDC and LC were incubated with 1 mM TNBS 
for 10 min (LC-TNBS), washed 3 times, injected in 100 pi HBSS/5% 
FCS s.c. (graded numbers of TNBS conjugated BMDC or 105 LC 
per mouse) into the dorsal skin of adult BALB/c mice. As a positive 
control, mice were sensitized by epicutaneous application of 100 pi 
of 3% TNCB to the abdomen. Mice were painted with the vehicle 
alone on the abdomen or alternatively injected with non-conjugated 
BMDC (negative control). Five days later, the right ears were painted 
with a 1% TNCB solution and ear thickness was measured 24 h 
later. TNBS-conjugated BMDC (10s) were able to induce a 
significant contact sensitivity response, which was comparable in 
magnitude to the responses generated by an equal number of 
TNBS-conjugated LC. Experimental groups consisted of five mice 
each. " P < 0.05 assessed by two-tailed Student's i-test. 
mice with 3% TNCB on the abdomen as described above, and 
harvested the brachial, axillary and inguinal lymph nodes 7 
days later. We purified the lymph node cells for CD4+ cells as 
described above and used them as responders in standard 
proliferation assays. As stimulators, we used BMDC conju-
gated or non-conjugated with TNBS. TNBS-conjugated BMDC 
were able to induce secondary responses in TNCB-sensitized 
T cells in vitro (Fig. 7). Furthermore, if we compared BMDC to 
cLC in their ability to present haptens, we found that these two 
cell types were equally efficient (Fig. 7). 
injection of TNP-conjugated DC induces contact 
hypersensitivity 
We next determined whether BMDC were able to present 
haptenated antigens in vivo. Consistent with previous 
studies (20,21) we found that naive BALB/c mice injected 
with graded numbers of TNP-modified or unmodified 
BMDC developed a contact sensitivity response upon 
TNCB challenge. Figure 8 shows that as few as 1 x 105 
TNP-conjugated BMDC were able to induce a significant 
contact sensitivity response, comparable in magnitude to 
the responses generated by an equal number of TNP-
conjugated LC. This finding is consistent with the in vitro 
results showing that there is no significant difference 
between BMDC and LC in presenting haptens. 
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Fig. 9. Heat-killed TNBS-modified BMDC do not sensitize for contact 
hypersensitivity. BMDC (3-5 x 105) were injected s.c. as 
unconjugated cells, TNBS-conjugated live cells (BMDC-TNBS, 
conjugation as described in Fig. 6.) or heat-killed dead cells (after 
conjugation ceils were cultured at 56°C for 50 min; cell viability 
assessed by Trypan blue exclusion was <3%). Positive and negative 
controls were carried out as in Fig. 4. Increase of ear thickness was 
measured 24 h after challenge. Heat-killed TNBS-conjugated BMDC 
(107) were not able to induce contact sensitivity. Experimental 
groups consisted of five mice each. Two-tailed Student's f-test was 
used for statistical analysis. 
Heat-killed TNP-conjugated BMDC fail to induce contact 
sensitivity 
To further investigate whether BMDC present the haptenated 
antigen themselves or whether shed antigens may be picked 
up and presented by host APC, we heat-killed the BMDC 
either before or after conjugation with TNP. The cells remained 
morphologically intact and >98% of the cells stained with the 
vital dye Trypan blue as revealed by microscopic examination. 
When these heat-killed cells were used there was no signifi-
cant contact sensitivity response detected. Figure 9 shows 
that even when large numbers (1 x 107) of TNP-conjugated 
heat-killed BMDC were used, contact sensitivity responses did 
not ensue. 
TNP-modified BMDC induce contact sensitivity in an MHC-
restricted manner as assessed both in vivo and in vitro 
To further evaluate whether any cross-presentation occurs 
during sensitization with BMDC, we harvested BMDC from 
BALB/c (l-Ad). If we harvested the draining lymph nodes 
after injecting TNBS-conjugated BALB/c-derived BMDC into 
BALB/c or C57BL/6 animals and re-stimulated with syn-
geneic TNBS-conjugated cLC in order to detect secondary 
T cell responses, we found that there were significant 
responses only when syngeneic cells were injected. 
C57BL/6 T cells harvested from mice injected with 
allogeneic BALB/c-derived TNBS-conjugated BMDC did 
not proliferate during co-culture with C57BL/6-derived 
syngeneic TNBS-conjugated LC (Fig. 10). 
Thereafter, we injected the TNBS-conjugated or non-
conjugated BALB/c- and C57BL/6-derived BMDC into 
parent and into Fi mice. Results obtained in three 
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Fig. 10. in vitro assessment of T cell responses after in vivo 
sensitization by TNBS-conjugated syngeneic or allogeneic BMDC. 
Primary sensitization of BALB/c (A) and C57BL/6 (B) mice was 
attempted with injection of 3 - 5 x 105 BALB/c BMDC that were 
conjugated with 1 it iM TNBS for 10 min, washed extensively 
(closed symbols) or by painting on the thorax and abdomen 
with 3% TNCB (hatched symbols). Draining lymph nodes were 
taken 6 days later, purified for CD4" T ceils, plated in 96-well 
f lat-bottom tissue culture plates (2 x 105 cell/ well) and co-
cultured with graded numbers of irradiated syngeneic BALB/c or 
C57BL/6 2-day cultured LC that were left unpulsed (squares) or 
were conjugated with TNBS as descr ibed in Fig. 6 (triangles). 
Significant T cell proliferation was detected only when syngeneic 
but not allogeneic TNBS-conjugated BMDC were used for the 
primary sensitization. There was no proliferation observed if mice 
were injected with non-conjugated BMDC or when non-
conjugated LC were used as stimulators. When cultured alone, T 
cells [non-stimulated or staphylococcal enterotoxin B (10 pg/ml) 
stimulated] as well as irradiated stimulators d id not proliferate. 
Data are representative of two independent experiments. 
Independent experiments (Fig. 11) showed that the TNBS-
conjugated BMDC induced contact sensitivity when in-
jected Into syngeneic mice and less, but still significant, 
contact sensitivity in F, mice. In contrast, if these cells 
were injected Into allogeneic hosts, these mice were 
unable to develop a contact sensitivity response. Thus, 
we were able to show, both by in vivo and in vitro assays, 
that BMDC present haptens and sensitize T cells in an 
M HC-restrlcted manner, and that, In keeping with the 
results of experiments using soluble protein antigens, 
cross-presentation of haptenated antigens could not be 
detected. 
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Fig. 11. TNBS-conjugated BMDC induce contact sensitivity in an 
MHC-restricted manner in vivo. BMDC were harvested from BALB/c 
and C57BL/6 mice, conjugated with 1 mM TNBS for 10 min, washed 
3 times, and 3 - 5 x 10s of these TNBS-conjugated (BMDC/BA-TNBS, 
BMDC/B6-TNBS) or non-conjugated BMDC (BMDC/BA, BMDC/B6) 
were injected s.c. in 100 pi HBSS + 5% FCS into the dorsal area of 
parenteral and F, adult mice. Mice were chal lenged 5 days later as 
descr ibed in Fig. 6 and ear thickness was measured 24 h later. 
Positive' and negative controls were carr ied out as in Fig. 6. TNBS-
conjugated BMDC sensitized syngeneic and, to a lesser extent, F, 
mice, but not allogenic mice. Each group contained five mice. The 
experiment shown is one of three independent experiments. One-
way ANOVA was used for statistical analysis. 
Discussion 
In this study, using in vitro and in vivo functional assays we 
determined the efficiency of BMDC as APC for protein- and 
hapten-restrlcted responses. BMDC cultured with GM-CSF 
and IL-4 for 8 days resembled DC with a highly mature 
phenotype. If cells were pulsed with soluble protein antigen 
during maturation, they Induced antigen-specific CD4+ T cell 
proliferation in vitro, suggesting that they effectively pro-
cessed and presented these antigens. Similarly, BMDC were 
able to present haptenated antigen to sensitized T cells in vitro, 
which Is consistent with previous findings (17,21,22). We also 
showed that exogenous proteins and haptens are presented 
In an MHC-restricted manner; that protein or hapten-pulsed 
BMDC were not able to Immunize allogeneic hosts; and that If 
parental (A) protein-pulsed BMDC were injected Into F-, (A x 
B) hosts, secondary T cell responses were detected only when 
T cells were re-stimulated with syngeneic parental (A) antigen-
pulsed APC. 
These findings demonstrate that haptens and proteins are 
not cross-presented to CD4+ T cells in vivo, and are In contrast 
to the phenomenon that has been shown for peptides 
presented in association with MHC class I molecules. 
Furthermore, the findings suggest that although uptake of 
apoptotic (13) and necrotic (15) cells by immature DC has 
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been demonstrated, functional cross-presentation might differ 
with MHC class II molecules compared to MHC class I 
molecules. The phenomenon of 'cross-presentation' [see 
review (23)], when antigens are transferred from cells or 
tissues and are represented on MHC class I and II molecules 
of APC, plays an important role In the maintenance of 
tolerance (24-26) and in the rejection of transplants (27-30) 
or tumor cells (31). It is known that immature DC present 
antigens from endocytosed particles, as shown for bacteria 
(32-34), apoptotic cells (13) and live cells (35). In their work, 
Albert et al. found that human blood-derived HLA-A2.1+ DC 
only presented the influenza matrix protein when derived from 
apoptotic HLA-A2.1" ceils; however, in a recent study Inaba 
et al. showed that processing of cellular fragments onto MHC 
class II may occur with both apoptotic and necrotic cells (15). 
Using Y-Ae mAb (36), which recognizes a complex of l-Ab-
presenting peptides from another MHC class II product, l-Ea, 
they found large amounts of Y-Ae+ cells In the T cell area of 
draining lymph nodes of C57BL/6 mice injected with live 
BALB/c-derived BMDC. These findings indicate that host APC 
picked up live injected BMDC either in the periphery or in the 
draining lymph node, therein potentially presenting peptides 
derived from the injected cells. Inaba et al. (37) have also 
shown this phenomenon and demonstrated that antigen-laden 
splenic DC can present antigen efficiently to unseperated 
lymph node T cells from mice with the same MHC products but 
not from allogeneic mice. Furthermore, Smith ef al. (38) found 
that despite the fact that peptide-pulsed CD8+ murine splenic 
DC did not migrate to draining lymph nodes after footpad 
Injection, they were able to stimulate a significant Th cell 
response. 
In our studies we used exogenous proteins and hapten, 
which were not previously assessed in cross-presentation 
studies, and our findings indicate that these antigens are not 
cross-presented to DC 4+ T cells by host APC. Furthermore, in 
our studies, necrotic (heat-killed) antigen-pulsed cells were 
not capable of sensitizing the host, even when large numbers 
were injected, suggesting that although necrotic cells are 
capable of inducing maturation of APC and of initiating potent 
immunogenicity of DC, these types of antigens are not 
represented by the host. This may be due to one of several 
reasons. It has been shown (39,40) using several transgenic 
lines expressing different amounts of ovalbumin (OVA) under 
the control of the rat insulin promoter that the level of antigen 
expressed by a cell must be above a certain threshold for 
cross-presentation to occur. It has also been suggested that 
because a cell expresses enough antigen to be recognized 
directly by an effector CTL, this does not mean that it will 
provide sufficient antigen for cross-presentation by profes-
sional APC (23). Based on our findings that BMDC required 
very high levels of soluble antigen to be able to prime naive T 
cells or induce antigen-specific secondary T cell proliferation, 
the antigen presented on the cell surface might still not be 
sufficient for cross-presentation by host APC. 
Recent findings showing cross-presentation of cell-associ-
ated OVA required 10 mg/ml of soluble OVA for pulsing spleen 
cells (41,42), a level significantly higher than the amount we 
used. In addition, cross-priming was shown to initiate CTL 
responses—there is little information about the Initiation of CD4 
responses. Using OT-I (CD8) and OT-II (CD4) TCR transgenic 
cell lines it has been demonstrated that cross-presentation of 
cell-associated OVA required 100-fold more OVA to stimulate 
CD4+ cells from OT-II mice when compared to CD8+ cells from 
OT-I mice (42). Although the authors emphasize that there is no 
way to determine whether the response of OT-I or OT-II cells 
reflects the strength of the response, or the ability to prime 
normal naive OVA-specific CD8 or CD4 cells, there may be a 
difference in the antigenic requirement for cross-presentation 
of MHC class I- and ll-associated molecules. The level of 
antigen exposure may be increased as the number of APC 
increases. However, even when we injected as much as 107 
cells per animal in order to expose the host to greater amounts 
of antigen we did not detect cross-presentation to CD4+ T cells 
or significant DTH or contact sensitivity responses. Taken 
together, these experiments increase our understanding about 
the potential in vivo immunogenic effects of BMDC used for 
vaccination and immunotherapy protocols. They show that, 
although cross-presentation of cell-associated and soluble 
antigens has been demonstrated, allogeneic or heat-killed 
soluble antigen-loaded BMDC are not capable of priming CD4 
T cells, indicating that cross-presentation of antigens pre-
sented In this way is inefficient. 
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Abbreviations 
APC antigen-presenting cell 
BM bone marrow 
CTL cytotoxic T lymphocyte 
CYT cytochrome c 
DC dendritic cell 
DCM dendritic cell medium 
DTH delayed-type hypersensitivity 
EC epidermal cell 
GM-CSF granulocyte macrophage colony stimulating factor 
HEL hen egg lysozyme 
LC Langerhans cell 
OVA ovalbumin 
PI propidium iodide 
PAM proliferation assay medium 
sMS syngeneic mouse serum 
TNCB trinitrochlorbenzene 
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Abstract 
Immunization with ex vivo generated dendritic cells has become a focus for many clinical applications. The optimal site of 
injection and the migration pattern of these cells remain to be elucidated. We therefore developed a novel method for labeling 
mouse bone marrow-derived dendritic cells (BMDC) with the positron emitting radioisotope F-18 using N-succinimidyl-4-[F-
18]f!uorobenzoate, which covalently binds to the lysine residues of cell surface proteins. When we determined the stability of F-
18 labeled BMDC, we found that at 4 h only 44 ± 10% of the initial cell-bound activity was retained at 37 °C, whereas 
considerably more (91 ± 3%) was retained at 4 °C. Labeled cells did not exhibit any significant alteration in cell viability or 
phenotype as determined by trypan blue exclusion and FACS analysis 24 h after radiolabeling. Furthermore, F-18-labeled 
BMDC stimulated allogeneic T cells in a mixed leukocyte reaction as potently as did sham-treated BMDC and migrated towards 
secondary lymphoid tissue chemokine (SLC) in a chemotaxis assay in vitro with the same efficiency as sham-treated BMDC. 
Migration of F-18-labeled BMDC was studied after footpad injection by (1) ex vivo counting of dissected tissues using a 
gamma counter and (2) in vivo by imaging mice with PiPET, a 2-mm resolution positron projection imager. After 4 h, the ratio 
between measured activity in draining vs. contralateral (D/C) lymph nodes (LN) was 166 ± 96 (n = l ) in the case of live cell 
injections, whereas if we injected heat-killed F-18-labeled BMDC or F-18-labeled macrophages the D/C ratios were 17 ± 2 
(n = 2) and 14 ± 4 (n = 2), respectively. Injection of cell-free activity in the form of F-18-labeled 4-fluorobenzoic acid resulted in 
a D/C ratio of 7 ± 2 (n = 3), suggesting that the activity measured in the draining lymph node was associated with migrated F-
18-labeled BMDC. When F-l 8-labeled live cells were injected into the footpad, 0.18 ± 0.04% (zt = 7) of footpad activity was 
found in the draining LN within 4 h, whereas none was found in the contralateral LN. Quantitative assessment of cell migration 
by PET projection imaging of mice confirmed the ex-vivo counting results. These studies indicate that PET imaging offers a 
Abbreviations: BMDC, bone marrow-derived dendritic cell; mAb, monoclonal antibody; PiPET, Projection Imager/Positron Emission 
Tomograph; SFB, N-succinimidyl 4-[F-18]-fluorobenzoate; FBA, 4-fluorobenzoic acid; M4>, macrophage; PI, propidium iodide; DCM, 
dendritic cell medium; LN, lymph node. 
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new approach for in vivo studies of dendritic cell biodistribution and migration. © 2002 Elsevier Science B.V. All rights 
reserved. 
Keywords: Dendritic cell; Migration; Positron Emission Tomography 
1. Introduction 
Active immunotherapy using tumor antigen loaded 
DC in mice have been extensively studied (Celluzzi et 
al., 1996; Porgador et al., 1996; Zitvogel et al., 1996; 
Lotze et al., 1997, 2000; Tuting et al., 1997; Fields et 
al., 1998a,b; Nestle et al., 1998; Salgaller et al., 1998). 
Other studies demonstrated protection against viruses 
(De Bruijn et al., 1998) and bacteria (Mbow et al., 
1997). Furthermore, human trials utilizing DC loaded 
with antigen are underway in several institutions. The 
induction of immunity depends on the interaction 
between DC and T cells. However, the best route of 
DC administration for ensuring migration to the T cell 
areas of lymph nodes, thereby ensuring optimal inter-
actions, is uncertain, in part, because the sites where 
human DCs localize after injection are not fully 
known. Although bone marrow-derived DCs (BMDC) 
or their precursors circulate in the peripheral blood 
and subsequently reside in peripheral tissues, acquire 
antigen and migrate to regional lymph nodes in 
physiological circumstances [Steinman, 1991 #63; 
Banchereau, 1998 #62; Flores-Romo, 2001 #1], the 
migration pattern is still under intensive investigation. 
Migration of dendritic cells after intravenous, intra-
dermal or subcutaneous injection has been assessed by 
using different tracing methods, such as membrane or 
cytosolic fluorescent dyes (Austyn et al., 1988; Bar-
ratt-Boyes et al., 1997; Ingulli et al., 1997; Lappin et 
al., 1999) or cells labeled with radionuclides such as 
Cr-51 (Cruz et al., 1990; Saeki et al., 1999) or Indium-
I l l (Kupiec-Weglinski et al., 1988; Larsen et al., 
1990; Morse et al., 1999; Thomas et al., 1999). In 
most of these studies the organs are removed at 
various times after injection of the label. 
The aim of our study was to develop a method to 
label DC with the positron emitting radionuclide F-18, 
in order to detect DC migration in vivo by a high-
resolution small animal PET camera. Here we 
describe our labeling method, the effects of labeling 
on the viability, phenotype and function of BMDC in 
vitro, and how F-18 labeled cells can be visualized 
and followed by a high resolution animal scanner. 
2. Materials and methods 
2.1. Mice 
Female BALB/c (I-Ad), C57BL/6 (I-Ab) and F1 
(BALB/cxC57BL/6) mice (6-10 weeks old) were 
obtained from the National Institutes of Health animal 
facility. All animals were treated in accordance with 
institutional protocol. 
2.2. Cells 
BMDC were generated using the method of Fields 
et al.' (1998a) with minor modifications. Briefly, bone 
marrow was flushed from tibias and femurs of female 
BALB/c or C57BL/6 mice and depleted of red blood 
cells with ammonium chloride. Cells were plated at 
1 x 106 cell/ml in T162 T flasks in 50 ml DC medium 
[(DCM: RPMI 1640 containing 5% FCS (Biofluids, 
Rockville, MD), 50 pM 2-ME (Sigma, St. Louis, 
MO), 10 mM Hepes (pH 7.4), 2 mM glutamine, 100 
U/ml penicillin, 100 (xg/ml streptomycin, and 20 jig/ 
ml Gentamicin (all from Life Technologies, Labora-
tories, Chagrin Falls, OH), supplemented with 10 ng/ 
ml GM-CSF and 10 ng/ml IL-4 (PeproTech, Rocky 
Hill, NJ)]. On day 5, cultures were fed with an 
additional 25 ml of DCM. On day 7 nonadherent 
and loosely adherent cells were harvested by vigorous 
pipetting of cultures. Harvested cells were resus-
pended in RPMI+ 5% FCS and 10 mM Hepes at 
5 x 106 cells/ml. Ten milliliters of this cell suspension 
were layered onto 15 ml of 14.5% metrizamide 
(Sigma) in RPMI+ 5% FCS and 10 mM Hepes 
solution in a 50-ml centrifuge tube and centrifuged 
at 1700 xg , 4 °C, for 10 min. The resulting cell 
interphase was harvested, washed twice in RPMI + 
5% FCS and 10 mM Hepes, and subcultured in DC 
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medium for an additional day. On day 8, non-adherent 
cells were harvested and these cells are referred to as 
bone marrow-derived dendritic cells (BMDC). The 
percentage of BMDC as determined by FACS analysis 
was routinely 85-95%. 
Inflammatory BALB/c skin macrophages (M$) 
were elicited by injection of sterile polyacrylamide 
beads (Bio-Gel P100, Biorad, Hercules, CA) in PBS 
(1.5 ml of a 50% suspension into the subcutis of the 
upper back), harvested after 5 - 7 days, enriched by 
plastic adherence and released from plastic by incu-
bating with 2 mg/ml glucose in PBS as described 
(Belkaid et al., 1998). 
2.3. Preparation of N-succinimidyl 4-[F-18]-fluoro-
benzoate (SFB) 
The F-18 labeled active ester was prepared in a 
three-step method. First, the trimethylanilinium triflate 
leaving group was displaced in the presence of Kryp-
tofix (K-222) (Aldrich, Milwaukee, WI) and potas-
sium carbonate (J. T. Baker, Phillipsburg, NJ) at 100 
°C for 10 min with [F-18] fluoride. Next the pentam-
ethylbenzyl ester was hydrolyzed to form 4-[F-18]flu-
orobenzoic acid with trifluoroacetic acid at room 
temperature for 2 min. Finally, the acid was converted 
to the F-18 labeled active ester, N-succinimidyl 4-
fluorobenzoate, with N f f -disuccinimidyl carbonate 
at 90 °C in 5 min. The final product was purified with 
reversed-phased HPLC. 
2.4. Radiolabeling 
1 - 3 x 107 BMDC in 1 ml HBSS (pH = 8) were 
labeled with 5 - 1 0 mCi of [F-18]SFB at room temper-
ature for 10 min. The cells were washed extensively 
with HBSS before labeling to remove FCS from the 
medium. In experiments using M<E>, 5 x 106 cells were 
labeled with 2 - 5 mCi [F-18] SFB under the same 
conditions as for the BMDC. Following incubation, 
the cells were washed three times with HBSS +5% 
FCS. Once the labeling and washing procedures had 
been completed, the labeling efficiency was measured 
with a gamma counter (Amersham Radioisotope Cal-
ibrator ARC-120). All subsequent F-18 counts 
described in the following sections were corrected 
for physical decay. The specific activity of the labeled 
cells was between 1 and 2 mCi per 1 - 3 x 107 BMDC. 
At a specific activity of F-18 at EOB of 200 mCi/ 
pmol, this would result in >107 F-18 per cell. 
2.5. Measurement of BMDC viability and radiolabel 
stability 
Viability of F-18-labeled BMDC was established 
by trypan blue (0.4%) (GibcoBRL) exclusion in a 
Burker hematocytometer after 24 h in culture. Viabil-
ity is expressed as percentage of viable cells among 
the total number of cells. The retention of radionuclide 
with BMDC was assessed by incubating F-18-labeled 
BMDC in DC medium at 4 °C or at 37 °C. Cells were 
incubated for 4 h. At 1 h intervals, equal aliquots were 
centrifuged for 5 min at 1200 rpm at 4 °C and cell and 
supernatant were assessed for radioactivity using a 
Packard 5600 gamma counter (Packard Instrument, 
Meriden, CT). 
2.6. Flow cytometry 
The phenotype of BMDC and M $ before and 24 h 
after labeling or after stimulation with 10 pg/ml 
stimulatory CD40 mAb (aCD40; HM40-3) was ana-
lyzed by flow cytometry using the following Abs: 
CDllc (HL3), CD 16/32 (2.4G2), CD54 (3E2), CD80 
(16-10A1), CD86 (GL-1), IAd (AMS-32.1) and iso-
type controls were purchased as purified, FITC-, or 
phycoerythrin-conjugated mAbs from PharMingen 
(San Diego, CA). Staining was performed according 
to standard techniques and cells were analyzed with a 
®FACScan flow cytometer using CellQuest software 
(Becton Dickinson, Mountain View, CA). No gating 
was performed, except for size and propidium iodide 
(100 nM; Sigma)-exclusion. 
2.7. Mixed lymphocyte reaction 
BALB/c-derived F-18-labeled and sham-treated 
BMDC were washed extensively, "(-irradiated with 
3000 rad, and added in graded numbers to allogeneic 
C57BL/6-derived naive T cells, which were harvested 
from peripheral lymph nodes and purified for CD4 + 
T cells with CD4 columns (R&D Systems, Minneap-
olis, MN). T cells were plated at 2 x 10s cells/well in 
96-well flat-bottom microplates (Costar) in RPMI 
1640 containing 10% heat-inactivated FCS, 10 mM 
Hepes (pH 7.4), 2 mM glutamine, 100 U/ml penicil-
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lin, 100 mg/ml streptomycin, 1% nonessential amino 
acids, 1 mM sodium pyruvate (all from Life Tech-
nologies), 50 pM 2-ME and 1 pg/ml indomethacin 
(Sigma). On day 4 of coculture 3H-thymidine (Amer-
sham International, Amersham, USA) (1 pCi/well) 
was added. T cell proliferation was determined by 
the incorporation of 3H-thymidine during the last 16 h 
of culture using a gas ionization counter (Packard, 
Meriden, CN). Results are presented as the mean 
± SEM of assays performed in triplicate. 
2.8. Chemotaxis assay 
BMDC were labeled with the intracellular fluores-
cent dye, calcein-AM (Molecular Probes, Portland, 
OR), at 1 pM for 30 min at 37 °C, washed extensively 
with HBSS and subsequently labeled with F-18, as 
described above, or with PBS (sham treated). A total 
of 25 x 104 cells in 25 pi of RPMI, 0.5% BSA, and 10 
mM HEPES medium were loaded on the top of the 
filter (ChemoTx 5 pm, Neuroprobe, Gaithersburg, 
MD). Murine SLC (R&D Systems) was placed in 
different concentrations in the bottom well to attract 
BMDC. After 4 h at 37 °C in a humidified incubator, 
the cells accumulating at the bottom of the chamber 
were enumerated in four randomly chosen 10 x 
views and averaged. Results are expressed as the 
mean ± SEM for duplicate wells. 
2.9. Dye labeling and detection of BMDC in LN by 
fluorescence microscopy 
Day 8 mature live or heat-killed (50 min at 56 °C) 
BMDC were labeled with the fluorescent dye PKH67 
(Sigma, St. Louis, MO) according to the manufactur-
er's protocol and injected (3-5 x 10s cells in 50 pi 
PBS) s.c. into left hind footpad of mice. The left 
popliteal LN was removed 48 h later, sectioned (6 
pm), air-dried without fixation and observed under the 
fluorescence microscope. 
2.10. Assessment of in vivo biodistribution and 
migration of BMDC by ex vivo gamma counter 
measurement 
Day 8 mature BMDC were labeled as described 
previously and 5 -10 x 10s cells (in 50 pi HBSS + 
5%FCS) were injected into the tail vein or the left 
footpad of BALB/c or B6 mice (n = 5/group). In some 
cases F-18-labeled BMDC were heat-killed (at 56 °C 
for 50 min), whereupon the cells remained morpho-
logically intact and more than 98% of the cells stained 
with the vital dye trypan blue. After heat-killing, the 
cells were washed and cell number as well as amount 
of radioactivity was adjusted to equal the live cells 
before injection. We injected the same number of cells 
and radioactivity in all conditions within one experi-
ment. Four hours after injection the mice were 
weighed, 1 ml blood was drawn from the retroorbital 
veins and, after euthanizing the mice, specific organs 
were taken, weighed and the radioactivity of F-18 was 
counted using a Packard 5600 gamma counter (Pack-
ard Instrument, Meriden, CT). Aliquots of the injected 
cell suspensions were counted simultaneously for 
accurate determination of the injected dose. The 
relative amount of radioactivity in the organs was 
calculated and expressed as the percentage of injected 
dose per gram of tissue (%ID/g) or, in some cases, as 
percentage of injected dose per organ (%ID/organ), 
and normalized to a 20-g mouse. 
2.11. Positron imaging 
Several animals were imaged to determine if the 
migration and biodistribution of BMDCs could be 
detected by external imaging. Based on the results of 
tissue assays, we elected to perform the initial "proof-
of-principal" imaging experiments on animals sacri-
ficed 4 h post-injection rather than on living animals. 
Tissue assays indicated that a very large fraction of the 
injected activity accumulated in the bladder, that 
much of the material remained in the footpad and that 
the smallest amount of activity was distributed over 
several different organs. In order to maximize the 
probability of detecting LN activity under these con-
ditions, the bladder was removed from each animal 
before imaging to eliminate this high activity source 
from in, or near, the imaging field-of-view. In addi-
tion, these experiments were performed with the 
PiPET (Projection Imager/Positron Emission Tomo-
graph) (Siegel et al., 1999) scanner configured for 
planar projection imaging. Although this 2-mra reso-
lution device is capable of high resolution rotational 
positron emission tomography, planar projection 
imaging is less susceptible to statistical uncertainties 
since the depth dimension is collapsed onto a two-
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dimensional plane. Although absolute quantitative 
accuracy and the depth location of activity are lost 
with this technique, in these initial experiments we 
sought only to locate activity to the LNs and to 
estimate the ratio of LN to footpad activity for 
comparison with tissue assay results. 
BALB/c mice, injected with 1 x 106 ( ~ 400 pCi) 
F-18-labeled BMDC, were prepared as described 
above and imaged for 10 min with PiPET such that 
the lower half of each animal, including the legs, was 
within the 55 mm x 45 mm field-of-view. In one 
study, the lower half of the animal was imaged first, 
followed by a translation of the animal such that the 
upper half of the body was in the field-of-view. The 
animal was imaged again and these two views com-
bined to create a decay corrected whole-body image 
of the entire animal. All images were analyzed using 
the NIH Image software package to obtain estimates 
of LN activity, footpad activity and background 
activity. The ratio of net LN/net footpad activity was 
then determined for each study for comparison with 
the results from tissue assays. The images were also 
inspected qualitatively to assess the apparent biodis-
tribution of the injected BMDCs at 4 h. 
2.12. Statistical analysis 
Experiments were performed at least twice. Mean 
differences were considered significant when p < 0.05 
(Student's i-test). 
3. Results 
3.1. Labeling efficiency and retention of radionuclide 
with BMDC 
The F-18 labeling efficiency—percentage of origi-
nal activity used for labeling remained with the cells 
after labeling and three washes—was 19 ± 4% (n = 18). 
Based on the specific activity of F-18, the cells were 
labeled with an average of 107 label/cell. Fig. 1 shows 
the distribution of F-18 in cells and supernatants as a 
function of time after labeling. At 37 °C considerable 
release occurred during the first hour and then re-
mained essentially unchanged. The release of F-18 
by BMDC may result from (1) spontaneous passive 
release; (2) active release due to cell metabolism and 
membrane turnover; (3) release from destroyed (i.e. 
disintegrated) cells; (4) passive release from dead (but 
intact) cells. To evaluate the extent to which cell me-
tabolism contributes to the release of activity we 
compared F-18 labeled BMDC which were kept at 
4 °C to F-18-labeled BMDC cultured at 37 °C in a 
humidified incubator. The percent of radioactivity 
retained with the cell pellet was only 42 ± 4% when 
the cells were cultured at 37 °C (Fig. 1), whereas 
BMDC maintained at 4 °C, retained 92 ± 2%, (Fig. 
1) indicating that cell metabolism and/or membrane 
turnover plays an important role in activity release by 
BMDC. To further evaluate the effect of labeling and 
the subsequent activity released, we assessed the per-
0 5 0 100 150 2 0 0 250 0 50 100 150 
Measured activity (CPM x 10"4) Measured activity (CPM x 10"4) 
Fig. 1. BMDC retain radionuclide better at 4 °C than at 37 °C. Average distribution of radioactivity in supernatants (hatched bars) and cell 
fractions (closed bars) for 4 h after labeling. BMDC were labeled with F-18 and either kept at 4 °C or incubated at 37 °C. Equal aliquots of 
cultures were centrifuged at different time points and the radioactivity associated with cells and in the supernatant was measured. While 
considerable activity was released when cells were incubated at 37 °C, far less activity was released when the cells were maintained at 4 °C. 
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centage of dead cells 4 and 24 h after labeling by trypan 
blue exclusion, and found that 95% and 90% of cells 
were viable after 4 and 24 h, respectively (data not 
shown). 
3.3. Labeling with F-18 has no significant effect on 
the ability of BMDC to induce allogeneic T cell 
proliferation or to migrate in an in vitro Chemotaxis 
assay 
3.2. F-18 labeling has no significant effect on the cell 
surface phenotype and maturation of BMDC 
To determine whether the F-18 labeling had any 
effect on the maturation of BMDC we labeled the 
cells (on day 8) during their incubation with stimula-
tory CD40 mAb. FACS analysis revealed that F-18 
labeling had no effect on the expression of I-Ad, 
CD80, CD86, CD54 and C D l l c (Fig. 2). Further-
more, as determined by PI staining, F-18 labeling did 
not affect cell survival; the percentage of PI positive 
cells were not significantly different in the two 
groups. 
Fig. 3 shows that when either F-18 labeled BMDC 
or control sham-treated BMDC were cultured for 5 
days with allogeneic T cells, both populations 
induced similar levels of secondary proliferation of 
T cells, indicating that labeling did not affect the 
ability of BMDC to induce a mixed leukocyte reac-
tion. It has been shown that mature BMDC express 
CCR7 (Dieu et al., 1998; Yanagihara et al., 1998), 
the receptor for the secondary lymphoid tissue che-
mokine (SLC), and that these cytokines play an 
important role in the trafficking of DCs from the 
periphery to the regional LN in vivo (Saeki et al., 
1999). When F-18-labeled BMDC were compared in 
C D 1 1 c lAd CD86 C D 8 0 C D 5 4 
7d BMDC 
Before labeling 
and stimulating 
9d BMDC 
Non-stimulated 
Non-labeled 
9d BMDC 
Non-stimulated 
F18-labeled 
9d BMDC 
aCD40-stimulated J 
Non-labeled 
9d BMDC 
aCD40-stimulated ! 
F18-labeled 
10° 101 I02 103 10° I0U 10' 10° 10' 
Fig. 2. F-18 labeling has no significant effect on the cell surface phenotype and maturation of BMDC. BMDC were cultured for 7 days, assessed 
by FACS analysis and then incubated with 10 pg/ml aCD40 mAb or medium for 2 days. After overnight culture with 10 pg/ml aCD40 mAb or 
medium, the cells were labeled with F-18. Twenty-four hours later, all cells were assessed by FACS analysis. Shaded areas—mAb of interest, 
unshaded areas—isotype control mAb. 
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Fig. 3. F-18 labeled BMDC function similarly to sham-treated 
BMDC in an allogeneic mixed leukocyte reaction and in an in vitro 
migration assay. Cells were labeled with F-18 (closed triangle) or 
were sham-treated (open square). (A) Twenty-four hours later, cells 
were •y-irradiated with 3000 rad, and added in graded numbers to 
2 x 105/well allogeneic C57BL/6-derived naive T cells. BMDC 
number was normalized by the percentage of class II+ cells by flow 
cytometry. Cell proliferation was measured on day 5 by counting 
[3H]thymidine (mean ± SE in triplicate wells) incorporation in the 
last 16 h of culture. Representative data from one of three similar 
experiments are shown. In the chemotaxis assay (B) BMDC were 
labeled with the intracellular fluorescent dye, calcein-AM at 1 pM 
for 30 min at 37 °C, washed extensively and subsequently labeled 
with F-18 (hatched bar), as described in Material and methods, or 
with PBS (sham-treated BMDC—closed bars). A total of 2.5 x 104 
cells were loaded on the top of the filter. Murine SLC was placed in 
different concentrations in the bottom well to attract BMDC. After 4 
h at 37 °C in a humidified incubator, the cells in the bottom of the 
chamber were enumerated in four randomly chosen 10 x views and 
averaged. Results are expressed as the mean ± SEM for duplicate 
wells. 
their ability to migrate towards SLC in trans-well 
chambers, there was no significant difference bet-
ween the F-18 labeled BMDC and the sham-treated 
BMDC (Fig. 3). 
3.4. BMDC migrate to the T cell areas of draining LN 
To confirm the migration capability of our BMDC, 
we labeled the cells with a stable membrane dye, and 
injected them into the footpad of mice. After 48 h, 
popliteal LN were removed and frozen sections were 
observed with a fluorescent microscope. BMDC 
migrated to the paracortical areas and subcapsular 
sinuses (T cell areas) shown at low magnification in 
Fig. 4b, Fig. 4a shows the same area under phase 
contrast microscope. To demonstrate that the observed 
fluorescence was associated with the injected cells and 
was not due to ingested dye from host migratory cells, 
we injected large numbers ( l x l 0 7 ) of heat-killed 
PKH67-labeled BMDC into the left hind footpad. 
After 48 h we were not able to detect any specific 
fluorescently staining cells in the draining popliteal LN 
as shown in Fig. 4d. 
3.5. In vivo biodistribution and migration of F-18-
labeled BMDC 
The biodistribution of F-18-labeled BMDC 4 h 
after intravenous administration is shown in Fig. 5a. 
Maximum %ID/g tissue is found in the lung fol-
lowed by the spleen, liver, kidneys, bladder, tail, ex-
tremities, plasma, blood cells, heart, ear and peripheral 
lymph nodes. These findings indicate that BMDC 
are first trapped in those organs with a dense 
capillary network like the lung and spleen and also 
that very few BMDC reach the peripheral lymph 
nodes or the ear skin. We decided to use s.c. in-
jection to validate our model, because of our and 
others (Curiel-Lewandrowski et al., 1999) consistent 
findings about the migration pattern of subcutane-
ously injected BMDC. Four hours after injection of 
F-18 labeled BMDC into the hind footpad, we found 
that the majority of the injected dose remained at the 
site of injection in the footpad, but there was 
significant activity detected in the draining lymph 
node as well as the liver, kidneys and the bladder 
(Fig. 5b). 
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Fig. 4. Fluorescently labeled BMDC migrate to T-cell regions of LN. Live (a, b) and heat-killed (c, d) BMDC were labeled with PKH67 (green) 
membrane dye and injected into the footpads of mice. Animals were killed 48 h later, and the popliteal LN draining the injected footpad were 
removed and frozen sections obtained for fluorescent microscopy. L:ve PKH67-labeled BMDC were found in the parcortical area and in the 
subcapsular sinuses (b), while heat-killed PKH67-labeled BMDC could not be detected in the draining lymph node (d). 
3.6. Cell-specificity of detected activity in the draining 
lymph node 
Our results regarding the stability of radiolabeling 
prompted us to try different approaches to identity 
whether the activity found in the draining lymph 
node was associated with migrated BMDC or was 
released activity filtered and accumulated in the 
lymph node. First we injected F-18-labeled cells that 
are thought not to migrate: (1) heat-killed BMDC 
and (2) Bio-gel-induced M<i>. In these experiments, 
we first labeled BMDC with F-18 and then incubated 
them for 50 min at 56 °C in order to kill the cells but 
mainta in their morphology. We prefer red this 
approach to the freeze-thawing procedure, because 
in the latter case cells are disrupted and debris is 
released. After heat-killing, the cells were washed 
extensively in order to remove released or non-cell 
bound activity and the dead cell number was 
adjusted to the number of live cells injected as 
controls. The other cells we used as controls were 
Bio-gel induced M4>, which we conjugated with F-18 
similarly to BMDC and injected the same amount of 
F-18-labeled M4> as control live F-18-labeled BMDC 
(Fig. 6). To further quantify the differences, we deter-
mined the ratio of cpm (draining popliteal lymph 
node)/cpm (contralateral popliteal lymph node = D/ 
C), which was 1 6 6 1 9 6 (« = 7) in the case of live 
cell injections, whereas with heat-killed F-18-la-
beled BMDC or F-18-labeIed macrophages the D/ 
C ratios were 1 7 1 2 (n = 2) and 1 4 1 4 (n = 2), res-
pectively. 
'r.r.i *,v T, v t \ 
• V Y l l W U / l K 1 
145 E.B. Olasz et al. / Journal of Immunological Methods 260 (2002) 137-148 
A) 
H 
5 10 
%ID/g Tissue 
15 
Lung 
Spleen 
Liver 
Kidney 
Bladder | | 
Tail- | h 
Extremities-
Plasma 
Blood cells-1 
Heart-
Ear-
Peripheral 
LN 
Pootpad 
Draining LN 
Heart 
Kidney-
Bladder 
Calf 
cFootpad 
cCalf 
cLN 
Plasma 
Blood Cells 
0 50 100 150 200 
%ID/ g Tissue 
Fig. 5. In vivo biodistribution and migration of F-18 labeled BMDC 
after intravenous and subcutaneous injection. Day 8 mature BMDC 
were labeled as described previously and 5 - 1 0 x 105 cells (in 50 pl 
HBSS + 5%FCS) were injected into the tail vein (A) or the left 
footpad (B) of BALB/c or B6 mice (n = 5/group). Four hours after 
injection, 1 ml blood was drawn from the retroorbital veins and after 
euthanizing the mice, specific organs were taken (c = contralateral), 
weighed and the radioactivity of F-18 was counted using a Packard 
5600 gamma counter (Packard Instrument, Meriden, CT). The 
relative amount of radioactivity in the organs was calculated and 
expressed as the percentage of injected dose per gram of tissue 
(%ID/g). 
Next we injected cell-free F-18 in the form of F-18-
labeled 4-fluorobenzoic acid (FBA) and resulted in a 
D/C ratio of 7 ± 2 (n = 3) and, interestingly, we found 
that there was minimal activity detected throughout 
the body. However, urine collected before euthanizing 
the mice suggested that F-18 is rapidly removed from 
the body through the kidneys, since we found a 
significant (60-80%) percentage of F-18 in the urine 
4 h after injection. To further evaluate the specificity 
of the labeling we injected radioactivity that was 
contained in the supernatant obtained after the first 
wash following the initial F-18 labeling as well as the 
supernatant f rom F-18 labeled B M D C that were 
cultured for 1 h at 37 °C. We found that neither F-
18 labeled 4-fluorobenzoic acid (FBA), nor the super-
natants gave significant activity in the draining lymph 
node 4 h after injection (Fig. 6). Thus we conclude 
that the measured activity in the popliteal lymph node 
was closely associated with the injected BMDC, 
which migrated into the lymph node. 
3.7. Positron imaging of F-18-labeled BMDC with 
PiPET 
Fig. 7 shows the whole-body projection image of 
a mouse imaged with PiPET 4 h after footpad injec-
tion with F-18-labeled BMDCs (after removal of 
the bladder). The footpad contains, by far, the largest 
Fig. 6. Radioactivity detected in the draining lymph node after 
injection with F-18 labeled BMDC is specific. F-18 labeled live and 
heat-killed BMDC, live macrophages ( M $ - F 1 8 ) , free F-18 
(FBA), the supernatant from the first wash after F-18 labeling and 
the supernatant obtained after culturing FI8-labeled BMDC for 1 h 
at 37 °C were prepared as described and injected into the hind 
footpad (n = 5/group). Cell numbers and radioactivity were 
normalized. Injected footpads (closed bars) and draining lymph 
nodes (hatched bars) were taken 4 h after injection, weighed and the 
radioactivity was counted using a Packard 5600 gamma counter 
(Packard Instrument, Meriden, CT). The relative amount of 
radioactivity in the organs was calculated and expressed as the 
percentage of injected dose per organ (%ID/organ). Significantly 
more radioactivity was found in the draining lymph nodes of mice 
that had received the F-18 labeled BMDC than was found when 
other labeled cells or supernatants were injected (*p<0.01) . 
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Fig. 7. PiPET image of a whole mice injected with F-18 labeled 
BMDC into the footpad. 5 x iO6 F-18 labeled mature BMDC were 
injected into the left hind footpad of naive BALB/c mice and 4 h 
later the mice were anesthetized and the bladder was removed. The 
mice were imaged for 10 min with the PiPET camera. Activity is 
found in liver, kidneys, draining popliteal lymph node and injected 
footpad. 
amount of activity in this image and is overexposed to 
allow lesser amounts of activity elsewhere in the body 
to be seen. The popliteal LN is readily visible by 
virtue of the BMDCs being intensely concentrated in 
a very small structure. The LN and the kidneys appear 
in their correct anatomical location. An additional 
accumulation of activity is also evident in Fig. 6 in 
the liver region. The second animal imaged with 
PiPET yielded an image of the LN and footpad region 
qualitatively similar to the lower half of Fig. 7. The 
ratio of net popliteal lymph node activity to net 
footpad activity determined from these images aver-
aged 0.15% for the two animals, a value that com-
pared well with ratios determined by tissue assay; 
average of 0.18%. Activity found in the lymph node 
as the percentage of the activity in the footpad was 
calculated as follows: (LN/FP ratio)=[Area x (Mean 
brightness — Background brightness)/Area of FP 
x (Mean brightness — Background brightness)] x 100. 
4. Discussion 
This is the first description of a method for labeling 
mouse BMDC with a positron emitting radionuclide 
F-18 in order to follow their migration with a high-
resolution imager in vivo. F-18 is a radionuclide with 
a short (109.7 min) half life, and a high specific 
activity (>200 Ci/mmol at EOB). The short half life 
allows detection of the radionuclide for a maximum of 
5 - 6 h, which in the case of BMDC migration is rather 
short, since the maximum number of injected BMDC 
can be found in the draining lymph node after 48 h in 
mice (Lappin et al., 1999). However, because of the 
availability of F-18 and its ability to be detected by 
PiPET, we decided to use this radionuclide for deter-
mining the possibility of monitoring in vivo migra-
tion. 
There have been several studies indicating the 
detrimental effects of isotope labeling of lymphocytes 
(ten Berge et al., 1983; Marcus, 1984; Kassis and 
Adelstein, 1985; Balaban etal. , 1987); however, more 
recent studies (Wagstaff et al., 1981; Botti et al., 1997; 
Kuyama et al., 1997) using either In-111 (Wagstaff et 
al., 1981) or l u I n - o x i n e , 1 8 F-FDG and " m T c -
HMPAO (Botti et al., 1997; Kuyama et al., 1997), 
report acceptable toxicity and potential uses of these 
labeling methods. 
Dendritic cells have been labeled with other radio-
nuclides (Kupiec-Weglinski et al., 1988; Cruz et al., 
1990; Larsen et a l , 1990; Saeki et al., 1999); how-
ever, we are not aware of any studies using F-18 
labeled BMDC. Therefore, it was crucial to determine 
the effect of the radiolabeling on these cells, in order 
to be able to use them in in vivo studies. Due to the 
short half life of F-18, our aim was to determine the 
short-term (max. 24 h) effect of the labeling. Labeling 
with F-18 had no significant effect on the viability or 
the phenotype of BMDC compared to sham-treated 
control cells, suggesting that these cells are fairly 
resistant to gamma and positron radiation. Further-
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more, using an in vitro chemotaxis assay we found no 
difference in the capacity of these cells to migrate in 
vitro compared to non-labeled DC. The short half life 
of F-18 did not allow us to perform long-term in vivo 
experiments; however, even at 4 h we could detect 
significant cell-bound activity in the draining lymph 
node. It was critical to determine whether the detected 
activity was related to cells or was free activity 
released by the labeled cell, because of the large 
amount of activity F-18 labeled cells released during 
in vitro culture. We tried to determine whether this 
release was passive shedding of membrane-bound 
activity or was related to cell metabolism, and found 
that release was significantly reduced if cells were 
kept at low temperatures in order to reduce their 
metabolic activity. The exact mechanism of this 
release requires further investigation. Better main-
tained radioactive labeling agents are also currently 
under development. However, using F-18 labeled 
macrophages, F-18 labeled dead BMDC or F-18 
labeled 4-fluorobenzoic acid for injection confirmed 
that the activity found in the draining lymph node 
after BMDC-F-18 injection represented cell-bound 
activity, since less activity was found in the case of 
controls. We chose footpad injections to establish the 
new method, based on previous in vivo migration 
experiments with fluorescent dye labeled BMDC. 
Previous studies in mice (Kupiec-Weglinski et al., 
1988) and in chimpanzees (Barratt-Boyes et al., 
1997) showed that after IV injection, DC accumulate 
first in lungs then in liver and spleen, organs in which 
injected cells are likely to lodge nonspecifically. 
PiPET imaging offers the possibility of studying in 
vivo cell migration, because radiolabeled cells can be 
detected in live animals. This method enables us to 
manipulate the animal during imaging, for example, to 
study the effects of certain chemokines or inflamma-
tory agents on the migration of the radiolabeled cells. 
Furthermore, this camera gives a ~ 2 mm spatial 
resolution, and has the potential to produce a 3D 
image. Using image analysis the exact amount of 
radioactivity can be determined and extrapolated to 
the number of cells. Furthermore, background activity 
can be subtracted to produce accurate quantitative 
measurements. Certain technical issues such as the 
proper anesthesia for mice while in the PET camera, 
and the effect of anesthetics on the migration need 
careful consideration. 
Our next goal is to develop a radiolabeling method 
with minimum loss of activity and maximum half life 
in order to be able to study the effect of certain anti-
inflammatory agents on the migration pattern of DC. 
This method currently provides the possibility of in 
vivo imaging with high accuracy and offers a new 
approach for in vivo studies of dendritic cell biodis-
tribution and migration. 
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A migratory population of skin-derived dendritic 
cells expresses CXCR5, responds to B lymphocyte 
chemoattractant in vitro, and co-localizes to B cell 
zones in lymph nodes in vivo 
Hidehisa Saeki, Meng-tse Wu, Edit Olasz and Sam T. Hwang 
Dermatology Branch, National Cancer Institute, Bethesda, USA 
Chemokine receptors on dendritic cells (DC) and chemokines within lymph nodes (LN) con-
tribute to trafficking of DC to appropriate sites within the LN. Here we show that DC that 
have migrated out of skin ex vivo (migratory DC, migDC) express 50-fold more CXCR5 
mRNA than fresh Langerhans cells and migrate in response to B lymphocyte chemoattract-
ant (BLC) in vitro. When injected into the footpad of mice, migDC emigrate to regional LN 
where up to 40 % are found in B cell zones. By contrast, murine bone marrow-derived DC 
display 14-fold less CXCR5, do not migrate to BLC in vitro, and migrate strictly to T cell 
zones in LN. We propose that activated skin DC utilize CXCR5 and BLC as a possible mech-
anism to home to B cell zones of LN, where they may have direct effects on B cells. 
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1 Introduct ion 
Dendritic cells (DC) are potent antigen-presenting cells 
that efficiently stimulate both B and T cells [1], To do so, 
antigen-bearing DC must leave peripheral tissue via 
afferent lymphatic channels and eventually enter discrete 
regions of the secondary lymphoid organs, such as 
spleen and lymph nodes (LN), where they meet T cells. 
At these sites, DC complete their maturation, perhaps 
through mechanisms related to CD40 ligation, and 
potentially attract T and B cells through the release of 
chemokines [2, 3]. 
Although DC are known to interact with T cells and can 
migrate to T cell zones in secondary lymphoid organs [4], 
recent publications clearly demonstrate that DC have 
several direct effects on B cells [5-7]. Different subpopu-
lations of skin DC have been described, including epider-
mal Langerhans cell (LC) and dermal types [1], Although 
similar in antigen-presenting capability [8], only dermal-
type DC have been found to stimulate naive B cells to 
synthesize antibodies [9], Recently, a CD11c* DC that 
[I 20608] 
Abbreviations: DC: Dendritic ceils migDC: Migratory DC 
BLC: B lymphocyte chemoattractant LC: Langerhans 
cells SLC: Secondary lymphoid tissue chemokine 
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was characterized by binding to a mannose receptor 
fusion protein (CRFc) has been demonstrated to accu-
mulate in B cell zones of the LN, but whether they 
migrated there from the periphery or altered their surface 
phenotype within the LN itself is unclear [10]. 
Chemokines and their corresponding seven trans-
membrane-spanning, G-protein coupled receptors play 
important roles in the migration of DC and B cells to sec-
ondary lymphoid organs [11, 12]. For example, MIP-3« 
(via CCR6) may attract immature DC to the epithelial 
crypts of the tonsils [13], while CCR7 and secondary 
lymphoid tissue chemokine (SLC) appear to play critical 
roles in the migration of DC to regional LN [14-16]. B cell 
chemoattractant (BLC) [17,18] and its receptor, CXCR5 
[19], have been shown to play an important role in B cell 
homing and lymphoid organogenesis [20]. BLC is highly 
expressed in the B cell follicles of secondary lymphoid 
organs [11, 17] and mediates efficient migration of B 
cells in vitro [17, 18]. To date, CXCR5 has only been 
shown to be expressed by B cells and a small subset of 
T cells [21]. Randolph et al. [22] have reported that 
CXCR5-transduced Th2 T cells accumulate in B cell folli-
cles in the spleen. 
Migratory DC (migDC) are skin-derived, activated DC 
that have migrated out of skin explants over the course 
of several days [23]. MigDC express high levels of CCR7 
and, when injected into the footpad of mice, they home 
to draining LN in an SLC-dependent fashion [14], Here 
© WILEY-VCH Verlag GmbH, D-69451 Weinheim, 2000 
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we show that migDC express 50-fold more CXCR5 
mRNA than resting LC, respond to BLC in vitro, and are 
capable of migrating to B cell zones within LN in vivo. We 
propose that the expression of CXCR5 may be a mecha-
nism by which DC migrate to B cell areas in secondary 
lymphoid organs. 
2 Results 
2.1 CXCR5 is expressed in a migratory 
population of skin-derived DC 
MigDC were analyzed for cell surface receptor expres-
sion by mAb and fusion protein staining using flow 
cytometry (Fig. 1). High levels of MHC class II and co-
stimulation molecules confirmed their activated pheno-
type. MigDC also showed little or no surface binding to 
the cysteine-rich domain of the mannose-binding protein 
fusion protein (CRFc) - a marker for a subpopulation of 
DC that apparently accumulate in B cell zones during 
some immune responses (not shown) [10]. 
We compared the quantitative expression of CXCR5 and 
CCR7 in several DC populations (Table 1): migDC, bone 
marrow-derived DC (BMDC), and fresh and cultured LC. 
LC cultured in an epidermal suspension for 3 days have 
an activated phenotype [24], CXCR5 expression in fresh 
LC was calculated to be approximately 50-fold lower 
than in migDC, whereas cultured LC expressed similar 
ig' i<r io" io in® to' iir w
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Table 1. Quantitative RT-PCR measurements of chemokine 
receptor mRNA expression in various DC populations4 
Purity CCR7 CXCR5 
Expression Expression 
relative to relative to 
Migratory DC Migratory DC 
Splenic B cells 95% 33 % 5100% 
Fresh LC 78% 0.09 % 2 % 
Cultured LC 89% 79 % 45% 
BMDC 90% 71 % 7% 
Migratory DC 90% 100 % 100 % 
Fig. 1. Surface staining profile of migDC by flow cytometry. 
Cultured skin-derived migDC were stained with directly con-
jugated antibodies as indicated. The filled histograms re-
present isotype control antibody staining. 
a) Splenic B cells, fresh LC, cultured LC, BMDC and migDC 
were isolated as described in Sect. 4.1. Expression is 
displayed relative to migDC (=100%). This single 
experiment was performed using means of duplicate 
samples and is representative of three separate 
experiments using semiquantitative RT-PCR methods. 
levels of CXCR5 compared to migDC. Since enrichment 
of l-Ad-positive cells from epidermal suspensions was 
necessary to observe CXCR5 expression by conven-
tional reverse transcription (RT)-PCR (data not shown), it 
was unlikely that keratinocytes expressed CXCR5. By 
contrast, splenic B cells, which are known to strongly 
express CXCR5, showed an approximately 50-fold 
higher expression of this receptor than migDC (Table 1). 
Thus, migDC and cultured LC have increased CXCR5 
message levels relative to fresh LC, but lower message 
levels than B cells. 
BMDC, as cultured in our protocol, were activated and 
expressed MHC class II levels similar to those observed 
for migDC (not shown). The BMDC expressed CCR7 at 
levels comparable to migDC, but expressed 14-fold less 
CXCR5 than migDC (Table 1). 
2.2 MigDC, but not BMDC, respond 
chemotactically to BLC in vitro 
To demonstrate that CXCR5 mRNA expression corre-
lated with function in migDC, we performed Chemotaxis 
assays using recombinant murine BLC as a stimulus and 
migDC and BMDC as targets. As shown in Fig. 2 a, BLC 
stimulated Chemotaxis of DC approximately 4-fold over 
baseline. Concentrations of BLC above 625 ng/ml {i.e. 
1,000 ng/ml) did not enhance migration of migDC. BLC 
was not as efficient as SDF-1 or SLC in inducing Chemo-
taxis (Fig. 2 b). By contrast, BMDC did not respond to 
BLC, but did respond to SLC with an 8-fold increase in 
migration (Fig. 2 c). By phase microscopy, > 95 % of all 
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(b) 
5 S5 125 
BLC (ng/ml) 
Control BLC SDF SLC 
Chemokines (ng/ml) 
Fig. 2. MigDC respond to BLC in vitro. Cultured migDC 
were used in mlcrochemotaxis assays with recombinant 
murine BLC, SLC, and human SDF-1rx as chemoattractants. 
(a) Dose response of migDC to BLC, (b) response of migDC 
to 100 ng/ml BLC, SDF-1«, and SLC, and (c) response of 
BMDC to BLC and SLC. Optimal migDC migration to SDF-
1« and SLC were achieved at 100 ng/ml in preliminary 
experiments. Results represent one of at least three experi-
ments with similar results. Results are shown as mean + 
SEM cells per field averaged from four fields per treatment 
condition. 
cells in BLC-stlmulated wells were dendritic In morphol-
ogy and were indistinguishable from SLC-stimulated or 
non-stimulated cells (not shown). Flow cytometric analy-
sis revealed that 98 % of all cells that had migrated to 
BLC were MHC class llhi°h in a pattern Indistinguishable 
from migDC that had migrated to SLC (not shown). Fur-
thermore, the cells that migrated to BLC did not show 
either specific B220 or CD3e staining (similar to SLC-
stimulated cells). Thus, the cells that migrated in 
response to BLC were neither B cells nor T cells and 
appeared to have classic morphological and surface 
phenotypic characteristics consistent with DC. 
2,3 MigDC migrate to B, as well as T, cell areas 
of the LN in vivo 
To address the question of whether expression of 
CXCR5 directed the migration of DC to specific areas of 
LN, we recovered migDC from skin, labeled the cells with 
a stable membrane dye, and injected them into the foot-
pad of mice. After 24, 48, and 72 h, popliteal LN were 
removed and stained with a B cell marker (CD45R/B220, 
Fig. 3 a) or a T cell marker (CD3e, Fig. 3 b) to delineate 
complementary B and T cell-rich areas. MigDC migrated 
to B cell zones as shown at low magnification In Fig. 3 c 
(white square region) and at high magnification in 
Fig. 3d. MigDC were also observed at the boundary 
zones between B and T cell zones [Fig. 3 c (red square 
region), e]. The majority of migDC were found in T cell 
zones (Fig. 3f). Not all B cell follicles in the LN contained 
visible DC (see Sect. 3). MigDC were also detected in 
subcapsular spaces (not shown). By contrast, BMDC 
localized exclusively to T cell areas (not shown), as 
reported recently [25]. To demonstrate that membrane 
labeling of the DC did not substantially alter the migra-
tion pattern of migDC, we also injected unlabeled migDC 
and BMDC into the footpad of mice. When LN from 
noninjected mice were sectioned and stained for CD11 c, 
positively stained dendritic-appearing cells were found 
predominantly in T cell-associated areas and not In B cell 
areas (not shown). After injection of BMDC, CD11c+ DC 
again appeared to be largely excluded from B cell areas 
(not shown). By contrast, after injection of migDC, 
CD11c' cells were visible in B cell-associated zones In a 
pattern consistent with that observed with labeled 
migDC (Fig. 3g, h). Quantification of the distribution of 
migDC from sections of LN at each time point indicated 
that up to 40 % of DC had migrated to B cell areas com-
pared to non-B cell areas by 48 h (Fig. 4). There was a 
tendency for more DC to be observed in B cell areas at 
48 h compared to 24 and 72 h, but DC could be clearly 
observed In B cell areas at both late and early time 
points. Thus, migDC appeared to migrate to B as well as 
T cell areas, whereas BMDC migrated almost exclusively 
to T cell areas. 
3 Discussion 
Our finding that activated migDC express CXCR5 and 
respond to BLC provides the first physiologically relevant 
mechanism for the migration of DC to B cell areas. Just 
as mature DC and naive T ceils are brought to LN via 
mechanisms related to CCR7 [14,15, 26], DC and B cells 
may utilize the same chemokine receptor, CXCR5, to find 
their way to B cell zones. However, because of the lack 
of suitable blocking reagents, we have not been able to 
determine whether BLC and CXCR5 are absolutely 
required for migDC trafficking to B cell areas; it Is quite 
possible that other chemokines and chemokine recep-
tors may also play a role in this process. Some DC popu-
lations (i.e. migDC) appear to express CXCR5 at suffi-
cient levels to respond to BLC, whereas others (i.e. 
BMDC) do not. This may explain why several studies 
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A 
B Cell 
Zone 
f f f i J ' frisk 
T cell zone 
Fig. 3. In vivo h o m i n g of f luorescent ly labeled m i g D C to d is t inct regions of LN. (a -b ) Sec t i ons of m o u s e LN were indiv idual ly 
s ta ined w i th F ITC-con juga ted a n t i - C D 4 5 R / B 2 2 0 (a) and F ITC-con juga ted an t i -CD3e (b) t o demons t ra te s ta in ing of c o m p l e m e n -
tary B and T cell regions, (c - f ) M i g D C were labeled w i th P K H 2 6 (red) m e m b r a n e dye and in jec ted into the f o o t p a d of mice. An i -
ma ls we re ki l led 24 , 48, or 72 h later, a n d the popl i tea l LN dra in ing the in jected f o o t p a d were removed and f rozen sec t ions 
ob ta ined for t w o - c o l o r con foca l m ic roscopy . Ail t he pho tos in (c - f ) were taken f rom the 48 -h t ime po in t , (c) M i g D C (red) w i th in B 
cel l zones (sta ined green w i th F ITC-con juga ted an t i -CD45R/B220) as wel l as T cel l zones (20x object ive), (d) The wh i te square 
region w i th in the B cell z o n e in (c) w a s imaged w i th a 6 0 x ob jec t i ve to demons t ra te indiv idual m igDC in red. (e) A border region 
b e t w e n B and T cell zones [ i l lustrated by the red square in (c) above] show ing m igDC, 6 0 x ob jec t ive , (f) M i g D C in a n o n - B cell 
(p resumab ly T cell) zone, 6 0 x ob ject ive, (g, h) Un labe led m igDC were in jected into f oo tpads . Sec t ions f r om the dra in ing popl i tea l 
LN were doub le -s ta ined w i th an t i -CD11c (g, M i g D C in red) or C D 4 5 R / B 2 2 0 (h, green) and imaged separate ly w i th red (g) and 
green (h) f i l ters by convent iona l immuno f luo rescence mic roscopy , 2 0 x ob ject ive. A r rows ind icate DC. 
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200 
S 1 5 0 -
100 
50 
B NON- B CELL AREA 
• B CELL AREA 
m 
i 
24HR-1 24HR-2 48HR-1 48HR-2 72HR-1 72HR-2 
Fig. 4. D is t r ibut ion of m i g D C in B and T cel l areas wi th in 
dra in ing LN. PKH26- labe led M i g D C were in jec ted into the 
f o o t p a d s of m ice (see legend t o Fig. 3). A t 24, 48, or 72 h 
after inject ion, the dra in ing popl i tea l LN w a s removed. Sec -
t ions f r om t w o di f ferent LN ( indicated by 24 HR-1 , 24 HR-2 , 
etc.) qual i tat ively s h o w i n g the h ighest n u m b e r s of to ta l 
m ig ra ted DC at each t ime point were s ta ined w i th FITC-
con juga ted a n t i - C D 4 5 R / B 2 2 0 t o ident i fy B cell zones. DC 
were coun ted th roughou t the ent i re LN by d i rect obse rva t i on 
w i th an ep i f luorescence m i c r o s c o p e and cons ide red t o fall 
w i th in B ceil areas if they were loca ted in areas s ta ined w i t h 
an t i -CD45R/B220 . Otherw ise , they we re c o u n t e d as be ing 
present in n o n - B cell areas. Each bar ref lects the total n u m -
ber of DC obse rved in a g iven LN sect ion, w i th s h a d e d a n d 
b lackened areas ind ica t ing the abso lu te n u m b e r s of DC 
wi th in n o n - B cell and B cel l areas, respect ively. 
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with splenic [4] and bone marrow-derived [25] DC found 
migration of these particular DC to T cell zones of LN. 
Of note, migDC did not appear to be distributed in all B 
cell follicles. Interestingly, while BLC was found to be 
expressed in most B cell follicles of spleen, BLC was var-
iably expressed in B cell follicles in peripheral LN [17], 
Thus, the pattern of migration we observed with migDC 
may reflect the higher expression of BLC in some of the 
B cell follicles of the LN. 
The subpopulation of DC described by Berney et al. [10] 
that migrated to B cell zones in LN was characterized by 
strong binding to the mannose receptor fusion protein, 
moderate to high expression of Fc receptors (CD16/32) 
and low CD80 expression - features that differed signifi-
cantly in migDC (Fig. 1). it remains to be determined 
whether these DC express CXCR5. We have not ruled 
out that additional phenotypic changes occur to migDC 
as they enter the cytokine environment of the LN. 
We have shown that skin-derived migDC up-regulate 
CXCR5 as they become activated and leave the skin in 
an ex vivo model of DC trafficking. MigDC functionally 
respond to BLC, which has previously been described 
exclusively as a B and (weak) T cell chemoattractant. In 
vivo this population of DC migrated from the footpad to 
regional LN, and up to 40 % of labeled migDC localized 
to B cell areas, although migDC were also apparent in T 
cell zones. Based on previous reports [14-16] and the 
strong expression of CCR7 by migDC, we propose that 
migDC initially utilize CCR7 to migrate to afferent lymph-
atics and/or SLC/ELC-rich T cell areas before migrating 
to B cell areas via CXCR5. Once in B cell areas, migDC 
may have direct effects on B cells as data from others 
have shown. Thus, the regulated expression of CXCR5 
on certain populations of DC may play a role in deter-
mining the migration pattern of DC within secondary 
lymphoid organs. 
4 Materials and methods 
4.1 Animals, reagents, and isolation of murine cell 
populations 
BALB/c female mice (8-12 weeks old) raised under specific 
pathogen-free conditions were used in all experiments, 
which were approved by the NCI Animal Care and Use Com-
mittee. Recombinant chemokines were purchased from 
R&D Systems, Minneapolis, MN (murine BLC) or Peprotech, 
Rocky Hill, NJ (human SDF-1 and murine SLC). All mAb for 
immunofluorescence tissue staining and flow cytometry, 
including biotin-, FITC-, or PE-conjugated mAb to murine 
l-Ad (AMS-32.1, mouse lgG2b), CD11c-PE (HL3, hamster 
IgG), CD16/32 (2.4G2, rat lgG2b), CD23 (B3B4, rat lgG2a), 
CD21/35 (7G6, rat lgG2b), CD80 (16-10A1, hamster IgG), 
CD45R/B220 (RA3-6B2, rat lgG2a), CD3e (145-2C11, ham-
ster IgG), and CD86 (GL1, rat lgG2a) and isotype control' 
mAb were purchased from Pharmingen (San Diego, CA). 
CRFc [10] was kindly provided by Drs. Siamon Gordon and 
Luisa Martinez-Pomares (Sir William Dunn School of Pathol-
ogy, University of Oxford, GB). 
BMDC were cultured using the method of Fields et al. [27] in 
RPMI 1640 with 5 % fetal calf serum (FCS), 50|iM 2-ME, 
10 mM HEPES (pH 7,4), 2 mM glutamine, 10 ng/ml GMCSF 
and IL-4 (Peprotech) in a volume of 50 ml with an additional 
25 ml of fresh medium added on day 5. On day 8, nonadher-
ent cells were harvested and layered onto 15 ml of 14.5 % 
metrizamide (Sigma)-RPMI 1640 plus 5 % FCS and 10 mM 
HEPES solution in a 50-ml centrifuge tube and centrifuged 
at 1,700xg at 4 °C for 10 min. The cell interphase containing 
BMDC (90-95 % pure by MHC class II expression) was col-
lected for use. 
For isolation of LC, epidermal suspensions [28] [fresh or 
after 3-day culture at 37 °C at 1 x 10s cells/ml in RPM11640 
with 10 % FCS (cRPMI)] were treated with FITC-conjugated 
anti-l-Ad, washed, exposed to anti-FITC antibody-coated 
micromagnetic beads (Miltenyi Biotech, Berg. Gladbach, 
Germany), and passed through a magnetic isolation column. 
Cells eluted after a second pass were approximately 78 % 
and 89 % pure for fresh and cultured epidermal LC, respec-
tively, by MHC class II expression analysis compared to 
2 -3 % LC in total epidermal suspensions. 
Murine migDC were isolated as described [23]. Briefly, 
mouse ears were separated along the cartilage plane, 
scraped of excess fat and connective tissue, and placed 
epidermis-side up in cRPMI medium. After 3 - 4 days at 
37 °C under 5 % C02l the skin was discarded and migratory 
cells were collected by centrifugation of the medium. 
Greater than 90% of the collected cells expressed high 
levels of MHC class II by FACS and were > 95 % viable by 
propidium iodide exclusion. 
Splenic B cells were isolated by preparing a suspension of 
spleen cells from BALB/c mice, labeling with FITC-
conjugated anti-CD45R/B220, and positive selection using 
anti-FITC antibody-coated micromagnetic beads as above. 
The resulting B cell population was > 95 % pure. 
4.2 Chemotaxis assays 
Murine migDC were used in Chemotaxis assays as 
described [14] using 8-|im (for migDC] and 5-um (for BMDC) 
pore size filters. Cells (25 nl containing approximately 
20,000 cells) were placed on top of the filters in duplicate. 
After 3 h at 37 °C, migrated cells that had fallen to the bot-
tom of the plate were photographed using a 4x objective. 
Four random views from two wells were counted using 
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Image Pro Plus (Media Cybernetics). By adding known num-
bers of cells to the lower chambers, we estimated that 70 % 
of total cells migrated to optimal concentrations of SLC 
(Fig. 2 b). Means and p values (Student's f-test, parametric, 
2-tailed analysis) were obtained using Instat (GraphPad 
Software, San Diego, CA). 
4.3 In vivo migration of skin-derived murine DC 
BMDC and migDC (300,000 cells in 50 pi Hanks' buffer with 
0.1 % bovine serum albumin) were either labeled with 
PKH26 (Sigma, St. Louis, MO) according to manufacturer's 
instructions or left unlabeled and injected into the left hind 
footpad of mice. The left popliteal LN was removed 24, 48, 
or 72 h later, sectioned (6 urn), air-dried without fixation, and 
stained with FITC-conjugated antiCD45R/B220 to identify B 
cell areas. T cell areas were stained directly with FITC-
conjugated anti-CD3e. When unlabeled DC were injected, 
LN sections were stained with biotin-conjugated anti-CD11 c 
followed by streptavidin-Cy3 to Identify DC. Isotype control 
staining showed negligible nonspecific staining. 
4.4 Quantitative RT-PCR 
Commercial kits for RNA extraction (RNeasy, Qiagen, Valen-
cia, CA) and reverse transcription (Superscript Preamplifica-
tion System, Glbco-BRL, Gaithersburg, MD) were used prior 
to amplification of specific cDNA using the following primer 
pairs selected from Genbank sequences listed In 5' to 
3' direction: CCR7 (GGACACGCTGAGATGCTCACT and 
CCATCTGGGCCACTTGGAT), CXCR5 (GACTCCTTACCA-
CAGTGCACCTT and GG AAACGGGAGGTGAACCA). 
Murine glyceraldehyde 3-phosphate dehydrogenase 
(CGTGTTCCTACCCCCAATGT and TGTCATCATACT-
TGGCAGGTTTCT) was used as an internal control for load-
ing. Real-time quantitative RT-PCR (Perkin-Elmer ABI7700) 
was performed with duplicate samples using SybrGreen dye 
for detection of double-stranded DNA. All primer pairs were 
designed to give products between 65 and 75 bp in length, 
gave rise to single band products, and had similar efficien-
cies of exponential amplification. Cycle threshold num-
bers (Ct) were derived from the exponential phase of PCR 
amplification. Fold differences In expression of gene x in cell 
populations y and z were derived by 2 \ where k = 
(Ct,-Ctc3P0H) populo1ion»-(Ct,-CtG3PDH) population z-
Acknowledgements: We wish to thank Drs. Mark C. Udey 
and Stephen I. Katz for helpful discussions. Expert technical 
assistance was provided by David J. Fitzhugh and Erik Gon-
zalez. 
References 
1 Banchereau, J . and Steinman, R., Dendritic cells and the con-
trol of immunity. Nature 1998. 392:245-252. 
2 Adema, G. J., Hartgers, F., Verstraten, R., de Vries, E., Mar-
land, G., Menon, S., Foster, J., Xu, Y., Nooen, P., McClanahan, 
T., Bacon, K. B. and Figdor, C. G., A dendritic cell-derived C-C 
chemokine that preferentially attracts naive T cells. Nature 1997. 
387: 713-717. 
3 Tang, H. L. and Cyster, J . G., Chemokine up-regulation and acti-
vated T cell attraction by maturing dendritic cells. Science 1999. 
282:819-822. 
4 Ingulli, E., Mondino, A., Khoruts, A. and Jenkins, M. K„ In vivo 
detection of dendritic cells antigen presentation to CD4* T cells. 
J. Exp. Med. 1997.185:2133-2141. 
5 Dubois, B., Vanbervliet, B., Fayette, J., Massacrier, C., Van 
Kooten, C., Briere, F., Banchereau, J. and Caux, C., Dendritic 
cells enhance growth and differentiation of CD40-activated B 
lymphocytes. J. Exp. Med. 1997.185:941-951. 
6 Dubois, B„ Massacrier, C., Vanbervliet, B., Fayette, J., Briere, 
F., Banchereau, J. and Caux, C., Critical role of IL-12 in dendritic 
cell-induced differentiation of naive B lymphocytes. J. Immunol. 
1998.161:2223-2231. 
7 Fayette, J., Dubois, B„ Vandenabeele, S., Bridon, J., Vanber-
vliet, B., Durand, I., Banchereau, J., Caux, C. and Brtere, F., 
Human dendritic cells skew isotype switching of CD40-activated 
naive B cells towards lgA1 and lgA2. J. Exp. Med. 1997. 185: 
1909-1918. 
8 Nestle, F., Filugueria, L., Nickoloff, B. and Burg, G., Human 
dermal dendritic cells process and present soluble protein anti-
gens. J. Invest. Dermatol. 1997.110: 763-766. 
9 Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-
Dambuyant, C., de Saint-Vis, B., Jacquet, C., Yoneda, K., 
Imamura, S., Schmitt, D. and Banchereau, J., CD34* hemato-
poietic progenitors from human cord blood differentiate along 
two independent dendritic cell pathways in response to GM-CSF ' 
+ TNFa. J. Exp. Med. 1996.184:695-706. 
10 Berney, C., Herren, S., Power, C. A., Gordon, S., Martinez-
Pomares, L. and Kosco-Vilbois, M. H., A member of the den-
dritic cell family that enters B cell follicles and stimulates primary 
antibody responses identified by a mannose receptor fusion pro-
tein. J. Exp. Med. 1999.190: 851-860. 
11 Cyster, J . G., Ngo, V. N., Ekiand, E. H., Gunn, M. D., Sedgwick, 
J. D. and Ansel, K. M., Chemokines and B-cell homing to folli-
cles. Curr. Top. Microbiol. Immunol. 1999.246:87-92. 
12 Cyster, J . G., Chemokines and the homing of dendritic cells to 
the T cell areas of lymphoid organs. J. Exp. Med. 1999. 189: 
447-450. 
13 Dieu, M.-C., Vanbervliet, B., Vicari, A., Bridon, J.-M., Oldham, 
E., Ait-Yahia, S., Briere, F., Zlotnik, A, Lebecque, S. and Caux, 
C., Selective recruitment of immature and mature dendritic cells 
by distinct chemokines expressed in different anatomic sites. 
J. Exp. Med. 1998.188:373-386. 
14 Saeki, H., Moore, A. M., Brown, M. J. and Hwang, S. T., Sec-
ondary lymphoid-tissue chemokine (SLC) and CCR7 participate 
in the emigration pathway of mature dendritic cells from the skin 
to regional lymph nodes. J. Immunol. 1999.162:2472-2475. 
15 Gunn, M. 0., Kyuwa, S., Tam, C., Kakiuchi, T., Matsuzawa, A., 
Williams, L. T. and Nakano, H., Mice lacking expression of sec-
ondary lymphoid organ chemokine have defects in lymphocyte 
homing and dendritic cell localization. J. Exp. Med. 1999. 189: 
451-460. 
2808 H. Saeki et al. Eur. J. Immunol. 2000.30:2808-2814 
16 Förster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-
Müller, I., Wolf, E. and Lipp, M., CCR7 coordinates the primary 
immune response by establishing functional microenvironments 
in secondary lymphoid organs. Cell 1999. 99:23-33. 
17 Gunn, M. D., Ngo, V. N., Ansel, K. M„ Ekland, E. H., Cyster, J . 
G. and Williams, L. T., A B-cell-homing chemokine made In lym-
phoid follicles activates Burkitt's lymphoma receptor-1. Nature 
1998. 391: 799-803. 
18 Legier, D. F., Loetscher, M., Roos, R. S., Clark-Lewis, I., Bag-
giollni, M. and Moser, B., B cell-attracting chemokine 1, a 
human CXC chemokine expressed in lymphoid tissues, selec-
tively attract B lymphocytes via BLR1/CXCR5. J. Exp. Med. 
1998.187:655-660. 
19 Dobner, T., Wolf, I., Emrich, T. and Lipp, M., Differentiation-
specific expression of a novel G protein-coupled receptor from 
Burkitt's lymphoma. Eur. J. Immunol. 1992. 22:2795-2799. 
20 Foerster, R., Mattis, A. E., Kremmer, E., Wolf, E., Brem, G. and 
Lipp, M., A putative chemokine receptor, BLR1, directs B cell 
migration to defined lymphoid organs and specific anatomic 
compartments of the spleen. Cell 1996.87:1037-1047. 
21 Förster, R., Emrich, T., Kremmer, E. and Lipp, M., Expression of 
the G-protein-coupled receptor BLR1 defines mature, recirculat-
ing B cells and a subset of T-helper memory cells. Blood 1994. 
84: 830-840. 
22 Randolph, D. A., Huang, G., Carruthers, C. J . L., Bromley, L. E. 
and Chaplin, D. D., The role of CCR7 in TH1 and Th2 cell localiza-
tion and delivery of B cell help in vivo. Science 1999. 286: 
2159-2162. 
23 Larsen, C. P., Steinman, R. M., Witmer-Pack, M., Hankins, D. 
F., Morris, P. J . and Austyn, J . M., Migration and maturation of 
Langerhans cells in skin transplants and explants. J. Exp. Med. 
1990.172: 1483-1493. 
24 Schuler, G. and Steinman, R. M., Murine epidermal Langerhans 
cells mature into potent immunostimulatory dendritic ceils in 
vitro. J. Exp. Med. 1985.161: 526-546. 
25 Lappin, M. B„ Weiss, J. M., Delattre, V., Mai, B., Dlttmar, H., 
Maier, C., Manke, K., Grabbe, S., Martin, S. and Simon, J . C., 
Analysis of mouse dendritic cell migration in vivo upon subcuta-
neous and intravenous injection. Immunology 1999. 98: 
181-188. 
26 Tangemann, K., Gunn, M. D., Giblin, P. and Rosen, S. D., A high 
endothelial cell-derived chemokine induces rapid, efficient, and 
subset-selective arrest of rolling T lymphocytes on a reconsti-
tuted endothelial substrate. J. Immunol. 1998.161: 6330-6337. 
27 Fields, R. C., Osterholzer, J . J:, Fuller, J . A., Thomas, E. K., 
Geraghty, P. J . and Mule, J . J., Comparative analysis of murine 
dendritic cells derived from spleen and bone marrow. J. Immuno-
ther. 1998. 21:323-329. 
28 Tamaki, K., Fujiwara, H. and Katz, S. I., The role of epidermal 
cells in the induction and suppression of contact sensitivity. 
J. Invest. Dermatol. 1981. 76: 275-278. 
Correspondence: Sam T. Hwang, Dermatology Branch, 
NCI, Building 10, Rm. 12N246, 10 Center Dr. MSC 1908, 
Bethesda, MD 20892-1908, USA 
Fax: +1-301-496-5370 
e-mail: hwangs@mail.nih.gov 
IMMUNOBIOLOGY 
CD200 is a novel p53-target gene involved in apoptosis-associated 
immune tolerance 
Michael D. Rosenblum, Edit Olasz, Jeffery E. Woodliff, Bryon D. Johnson, Marja C. Konkol, Kimberly A. Gerber, 
Rimas J. Orentas, Gordon Sandford, and Robert L. Truitt 
During apoptotic cell death, biochemical 
processes modify self-proteins and cre-
ate potential autoantigens. To maintain 
self-tolerance in the face of natural cell 
turnover, the immune system must pre-
vent or control responses to apoptosis-
associated autoantigens or risk autoim-
munity. The molecular mechanisms 
governing this process remain largely 
unknown. Here, we show that expression 
Introduction 
of the immunoregulatory protein CD200 
increases as murine dendritic cells (DCs) 
undergo apoptosis. We define CD200 as a 
p53-target gene and identify both p53-
and caspase-dependent pathways that 
control CD200 expression during apopto-
sis. CD200 expression on apoptotic DCs 
diminishes proinflammatory cytokine pro-
duction in response to self-antigens in 
vitro and is required for UVB-mediated 
tolerance to haptenated self-proteins in 
vivo. Up-regulation of CD200 may repre-
sent a novel mechanism, whereby im-
mune reactivity to apoptosis-associated 
self-antigens is suppressed under steady 
state conditions. (Blood. 2004;103: 
2691-2698) 
© 2004 by The American Society of Hematology 
As a result of natural ccll turnover, cells in peripheral tissues 
continually undergo apoptosis. These apoptotic ceils arc associated 
with a distinct lack of inflammation, leading to the initial percep-
tion that the process of apoptosis is immunologically silent and 
passive.1 However, it is now clear that apoptotic cells do not just 
quietly disappear. Instead, they actively inhibit immune responses 
by providing immunoregulatory signals directly to cells of the 
immune system. For example, when added to human lymphocyte 
cultures stimulated with lipopolysaccharide, apoptotic cells inhibit 
production of proinflammatory cytokines such as tumor nccrosis 
factor et (TNF-tx), interleukin 1 (IL-1), and IL-12 and promote the 
production of the anti-inflammatory cytokine IL-10.2 T-cell activa-
tion is inhibited when apoptotic cells are added to splenocytes in 
the presence of Con A.2 Macrophages that have ingested apoptotic 
cells increase production of anti-inflammatory cytokines and 
inhibit production of proinflammatory cytokines.4 Furthermore, 
immature dendritic cells (DCs) that have taken up apoptotic cells 
have a compromised ability to mature into immunostimulatory 
antigen-presenting cells (APCs).5 
Given their immunosuppressive capacity, it has been suggested 
that apoptotic cells generated during natural cell turnover play a 
central role in the establishment and maintenance of peripheral 
self-tolcrancc.6 Immature DCs and monocytes traffic through 
tissues, phagocytose apoptotic cells, and migrate to lymphoid 
tissue7; DCs that have ingested apoptotic cells process and present 
apoptotic cell-derived peptides on major histocompatibility com-
plex (MHC) class I and class II molecules8; and DCs that have 
taken up apoptotic cells fail to initiate productive T-cell responses, 
possibly through the induction of regulatory T cells.9-10 Patients 
with autoimmune diseases have abnormal immune responses to 
self-peptides generated during apoptosis, suggesting that mecha-
nisms exist in healthy individuals that suppress immunoreactivity 
to apoptosis-associated self-antigens." 
DCs are among the cells that continually turnover in peripheral 
tissues,12"14 and apoptotic DCs have been shown to play a role in 
apoptosis-linked peripheral tolerance through their interaction with 
lymph node-resident DCs.6-13 The molecular mechanisms that 
govern this process, however, have not been identified. 
CD200, formerly known as OX-2, is a highly conserved type I 
transmembrane glycoprotein that is expressed on a variety of cell 
types, including DCs.15 Expression of the receptor for CD200 
(CD200R) is restricted to myeloid-derived APCs and certain 
populations of T cells.16-17 Several studies have shown that CD200 
imparts an immunoregulatory signal through CD200R, leading to 
the suppression of T-cell-mediated immune responses. Increased 
allograft survival following portal vein immunization with alloanti-
gen correlates with an increase in CD200 expression on both 
hepatic and splenic DCs.18 Tolerance in this setting is reversed with 
a monoclonal antibody to CD200.19 CD200+ DCs or soluble 
CD200 decrease typc-1 cytokine production (interferon y [IFN-y] 
and IL-2) and promote production of type-2 cytokines (IL-4, IL-10, 
and TGFP) in vitro and prolong allograft and xenograft survival in 
vivo.20-21 CD200-deficient mice have a compromised capacity to 
down-regulate APC activation in the steady state, resulting in 
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chronic central nervous system inflammation, an exaggerated 
inflammatory response to trauma and an increased susceptibility to 
develop both experimental autoimmune encephalitis and collagen-
induced arthritis.22 
Taken together, these and other studies provide evidence that 
CD200-CD200R signaling results in the down-regulation of im-
mune responses and that in the absence of CD200 tolerance to 
peripheral self-antigens is easily broken. 
The molecular mechanism(s) controlling CD200 expression and the 
immunologic context (ie, steady state, inflammation) in which DCs 
express CD200 are not yet fully defined. Experiments in our laboratory 
revealed that CD200 expression in vivo and in vitro was increased on 
DCs undergoing apoptosis. Here, we examined the hypothesis that 
CD200 expression increases with apoptosis and that CD200 on apopto-
tic DCs mediates an immunoregulatory signal that leads to immune 
tolerance. We show that CD200 expression increases as murine DCs 
undergo apoptosis, that the gene for CD200 contains functional p53 
response elements, that both p53- and caspase-dependent pathways 
control expression of CD200 during apoptosis, that CD200 expres-
sion on apoptotic DCs diminishes proinflammatory cytokine pro-
duction in response to apoptosis-associated self-antigens in vitro, 
and that CD200 is required for UVB-nrediated tolerance to 
haptenated self-proteins in vivo. 
Materials and methods 
Mice 
CS7BL/6 mice (B6) were purchased from Jackson Laboratories (Bar 
Harbor, ME). CD200 - / - mice (derived in the B6 background22) were 
provided by Dr Jonathan Sedgwick (DNAX Research Institute, Palo Alto, 
CA). Age- and sex-matched mice were used in all experiments. 
DC isolation, induction of apoptosis, and flow cytometry 
Isolation of splenic DCs was carried out as previously described.23 Briefly, 
spleens were minced and collagenase digested. CDllc*' DCs were isolated by 
double column selection using CD1 lc microbeads and an AutoMACS immuno-
tnagnetic cell separator (Miltenyi Biotec, Auburn, CA). Positive fractions were 
consistently more than 97% CD1 lc'*. DCs were cultured in Dulbecco modified 
Eagle medium (DMEM) with 3% heat-inactivated fetal bovine serum (FBS) 
supplemented with 5 X 10 s M 2-mercaptocthanol (Sigma, St Louis, MO), 
HEPES (/V-2-hydroxycthylpiperazine-/V'-2-elhancsulfonic acid) buffer (10 mM), 
sodium pyruvate (1 mM). penicillin (100 U/mL), streptomycin (100 pg/mL), 
L-glulamine (2 mM), and minimum essential medium amino acids (referred to 
hereafter as complete DMEM) at 37°C in 5% C02. All components were from 
Gibco BRL (Grand Island, NY) unless otherwise specified. DCs were cultured in 
complete DMEM at I X 10° cclls/mL in round-bottom 96-microwell plates to 
induce apoptosis. Flow cytometry reagents include the following: anti-CD200 
antibody (3B6; phycoerythrin [PE]; Tetralink, Buffalo, NY; and/or OX-90; 
biotin), rat immunoglobulin M (IgM) isotype control (R4-22; PE), I-Ab (KH74; 
biotin), CD80 (16-10A1: PE), CD86 (GL1; fluorescein isothiocyanate [FITC]), 
CD40 (HM40-3; FITC), or CaspACE FITC-VAD-FMK (Promega, Madison, 
WI). All antibodies were from BD PharMingen (San Diego, CA) unless 
otherwise stated. Annexin V versus 7-amino-aetinomycin D (7-AAD) staining 
was performed according to the manufacturer's instructions (BD PharMingen) 
after antibody staining. On the basis of their Annexin V versus 7-AAD staining 
pattern, CDllc* DCs were sorted into nonapoptotic and apoptotic cells on a 
fluorescence-activated cell sorting (FACS) DiVa cell sorter (BD Inrmunocytom-
etry Systems). Sorted fractions were then analyzed for CD200 expression. 
RT-PCR 
CDl lc* ceils were isolated (as described in "DC isolation, induction of 
apoptosis, and flow cytometry") and cultured in complete DMEM. At 
various times after culture, cells were harvested, and total RNA was 
extracted with TRIzol according to manufacturer's instructions (Life 
Technologies, Rockvillc, MD). RNA was quantified and equal amounts (—I 
p,g) were reverse transcribed into cDNA with oIigo(dT) primers using 
Thcrmoscript reverse transcriptase-polymcrasc chain reaction (RT-PCR 
systems (Gibco BRL) according to the manufacturer's instructions. Semi-
quantitative RT-PCR was performed by using CD200 (S'-AGTGGTGAC-
CCAGGATGAA-3' 5'-TACTATGGGCTGTACATAG-3') or (3-actin (5'-
GAGTCCTGTGGCATCCACG-3' 5 '-CTAGGAGCATTTGCGGTGGAC-
3') primer sets. In this procedure, a maximum of 40 PCR cycles was 
consecutively reduced by 5 or fewer cycles to determine relative quantities 
of CD200 or P-actin cDNA. Densitometry was performed directly on 
agarose gels using Alpha Imager 2200 v5.5 software on an Alpha Imager 
2200 (Alpha Innotech, San Leandro, CA). 
Quantitative real-time RT-PCR was performed on RNA isolated at 
various times after culture by using preformulated CD200 and 18S rRNA 
Gene Expression Assay systems according to manufacturer's protocol 
(Applied Biosystems, Foster City, CA). Reactions were carried out in an 
Opticon-2 Continuous Fluorescence Detector (MJ Research, Boston, MA). 
Data were analyzed. by using the comparative Ct method (Applied 
Biosystems). 
Identification of p53REs and p53 luciferase studies 
Nucleic acid sequences were obtained from the National Center for 
Biotechnology Information "Entrez nucleotide" sequence database (http:// 
www.ncbi.nlm.nih.gov/entrez). Accession numbers were as follows: mu-
rine CD200 gene, AH006102; human CD200 gene, Contig no. NT_00595.14 
(region spanning 2791473-2821185). Sequences were analyzed for the 
consensus p53REs as described in "Results" with Lasergene sequence 
analysis software (DNASTAR, Madison, WI). 
The following pairs of oligonucleotides encompassing the first putative 
p53 response element (p53RE no. 1) and the second putative p53 response 
clement (p53RE no. 2) from the first inlron of the human CD200 gene were 
commercially synthesized: p53RE no. la, 5'-AGCTAAACTTGCTGAG-
GAAGAGGCATGAAT-3'; p53RE no. lb, 5'-GATCATTCATGCCTC-
TTCCTCAGCAAGTTT-3'; p53RE no. 2a, 5'-AGCTGAGCTTGTCCAT-
TCTGCATTCTTCATCATGGCC-3'; p53RE no. 2b, 5'-GATCGGCCATG-
ATGAAGAATGCAGAATGGACAAGCTC-3'. As control, the following 
oligonucleotides encompassing randomly chosen sequence from the first 
intron of the human CD200 gene were also commercially synthesized: 
control-a, 5'-AGCTTAGTGCTTATTTCTACTGGCAGTATT-3'; con-
trol-b, 5'-GATCAATACTGCCAGTAGAAATAAGCACTA-3'. Oligonucle-
otides of each pair were annealed, resulting in double-stranded oligonucleo-
tides with extremities compatible with a 5'HindlU and 3'fig/ll digestion 
product. Double-stranded oligos were cloned into the pLUC-MCS plasmid 
(Stratagene, La Jolla, CA) digested with Hindi 11 and Bglll. Either of these 
constructs (pLUC-MCS-p53RE no. 1. pLUC-MCS-p53RE no. 2, orpLUC-
MCS-control) were cotransfected into pS3-deficient NCI-HI299 cells24 
(American Type Culture Collection, Rockville, MD) with or without 
pFC-p53 (Stratagene), a plasmid that constitutively expresses wild-type 
human p53. Cotransfections were carried out in 6-well culture plates using 
PoiyFect transfection reagent according to manufacturer's instructions 
(Qiagen, Valencia, CA). Equivalent amounts of a vector that constitutively 
expresses green fluorescent protein (GFP) were used in replicates of each 
experiment to control for transfection efficiency. Luciferase activity was 
measured 24 to 48 hours after transfection by using a luciferase assay kit 
according to the manufacturer's instructions (Stratagene) with an AutoLu-
mat LB9S3 bench top luminometer (Berthold Systems, Aliquippa, PA). 
Autologous mixed lymphocyte reaction (MLR) cultures 
CDllc* cells were incubated for 24 hours in complete DMEM to induce 
apoptosis before the addition of responder cclls. Approximately 70% of 
DCs were Annexin V* at the time responder cclls were added. For caspasc 
inhibition experiments, CD 1 lc* cclls were cultured in complete DMEM in 
the presence or absence of 200 pM Z-VAD-FMK (Promega) for 18 hours. 
Cells were washed 3 times and used as stimulator cells. CD4* responder T 
cells were obtained from the spleens of B6 mice by double-column 
selection using anti-CD4 microbeads and the AutoMACS. Cells were 
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Figure 1. Splenic DCs increase expression of CD200 on 
the cell surface as they undergo apoptosls. (A) Freshly 
isolated splenocytes from WT C57BL/6 or CD200-'- mice 
were quadruple stained with CaspACE, anti-CD200 mAb, 
CD11c, and 7-AAD. Ceiis shown are 7-AAD" and CD11c*. 
Numeric values denote the percentage of cells in each quad-
rant. (B) CD11 c* DCs were cultured In complete DMEM for 24 
hours and assayed for cell size (FSC) versus CD200 expres-
sion. Quadrants are arbitrarily set on the basis of minimal 
(< 5%) staining with isotype control antibody. Numeric values 
denote the percentage of CD200" cells. (C) CD11c" cells 
were cultured in complete DMEM for 24 hours and sorted into 
either nonapoptotic (Annexin V /7-AAD ) or apoptotic (An-
nexin V/7AAD ' ! ) populations, and CD200 expression was 
examined. (D) CD11c! cells were cultured incomplete DMEM 
for 18 hours and triple stained with CaspACE, 7-AAD, and 
antl-CD200 mAb. Electronic gates were set on nonapoptotic 
(CaspACE /7-AAD ), early apoptotic (CaspACE*/7-AAD ), 
or late apoptotic (CaspACE ' /7AAD1) cells, and CD200 expres-
sion was examined. (C-D) Shaded and unshaded histograms 
represent staining with anti-CD200 and Isotype control mAbs, 
respectively. AGnleai. values represent the change In MFI 
between anti-CD200 and isotype control staining. Results are 
representative of 3 replicate experiments. 
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routinely more than 9 8 % C D 4 + af ter separat ion. C D l l c " s t imulator cells 
(5 X 105) were added to 2 X 105 C , D 4 + r e s p o n d e r T cells. All cul tures were 
carried out in comple te D M E M in triplicate round-bot tom microwells . 
Culture wells were pulsed with 1 p.Ci/mL (0.037 MBq/mL) [ 3 H)- thymidine 
at 72 hours and thymidine incorporat ion was measured 12 hours later. 
Cytokine analysis 
Cytokine levels were measured f rom culture supernatants using cytometr ic 
bead arrays (CBA; B D Biosciences . San Diego, CA) according to the 
manufac turer ' s protocol . "Expe r imen ta l " values were expressed as a 
percentage of CD200'"''"" controls for each cytokine. Normal ized values 
f rom replicate exper iments were pooled and compared with the C D 2 0 0 " 
control (ic, 100%) by Student / test. 
UVB contact hypersensit iv i ty studies 
Contact hypersensit ivity exper iments were done as previously described.2 5 
Briefly, the abdomens of m i c e were shaved, and groups o f 5 mice were 
irradiated with 400 J/m2 U V B using a bank o f 4 UVP-AB-111 midrange UV 
tubes (UVP, Upland, CA) emit t ing between 280 and 360 nm with a peak at 
302 nm. Mouse ears were protected f rom U V B . Five control mice were 
shaved but not exposed to U V B . Mice were irradiated 4 consecut ive t imes 
over 4 days. Twenty- four hours later, irradiated and control mice were 
sensitized by apply ing 25 p,L 0 .5% D N F B (2,4-dini tro-f luorobenzene; 
Sigma) diluted in acetone/ol ive oil (4:1) on the shaved abdominal skin. Five 
days later, mice were chal lenged with 5 p,L 0 .15% DNFB on each side of 
the right ear. Before chal lenge, basel ine ear th ickness was measured . Af ter 
challenge, ear th ickness was measu red at 24 and 48 hours. Ear swel l ing was 
calculated by subtract ing basel ine values f r o m the values recorded on 
subsequent days. 
Results 
CD200 expression increases during apoptosis 
DCs continually undergo apoptosis in the steady state.13'23 By using 
CaspACE (F1TC-Z-VAD-FMK), a cell-permeable reagent that 
labels apoptotic cells by binding specifically to activated caspases, 
we found that more than 70% of freshly isolated apoptotic CD1 l c + 
DCs expressed CD200, as compared with 35% of nonapoptotic 
DCs (Figure 1A). We next examined both the kinetics and 
mechanism of CD200 expression on DCs as they undergo apopto-
sis. When cultured in vitro, splenic DCs spontaneously undergo 
apoptosis as a result of growth factor deprivation.26 By using this 
simple technique, we correlated CD200 expression with 3 estab-
lished markers of apoptosis: reduction in cell size, inversion of 
phosphatidylserinc, and activation of caspases. At various times, 
cultured DCs were collected and analyzed for forward light scatter 
(FSC) and CD200 expression. There were more than twice as many 
CD200+ cells after 24 hours of culture (29% versus 12%; Figure 
IB) when approximately 70% of the cells were apoptotic based on 
Annexin V staining (Figure 2A). The high CD200-expressing 
population was restricted to the smaller cells identified by de-
creased FSC (Figure IB). To confirm that apoptotic DCs expressed 
higher levels of CD200, we sorted Annexin V + and Annexin V" 
cells and stained them with anti-CD200 monoclonal antibody 
(mAb; Figure 1C). Although a low level of CD200 expression was 
observed on some nonapoptotic DCs (Annexin V /7-AAD ), there 
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Figure 2. CD200 mRNA expression as DCs undergo apoptosis. (A) CD11c* cells were isolated and cultured in complete DMEM to induce apoptosis. Numeric values denote (B) 
semiquantitative RT-PCR for CD200 and p-actin. Numbers adjacent to gel represent densitometry values for above spots. (C) Quantitative real-time RT-PCR for CD200 and18S rRNA 
were performed on mRNA isolated at various times after culture. Results are representative of 3 replicate experiments. "Statistically significant from 0 hour (P < .05) by Student f test. Error 
bars indicate ±1SD. 
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was a pronounced increase in CD200 expression on apoptotic DCs 
(Annexin V + /7-AAD" / + ) . Because activation of caspases is a 
hallmark of apoptotic cell death, we used CaspACE, along with 
7-AAD and anti-CD200 mAb to assess CD200 levels on early and 
late apoptotic DCs. CD200 expression on nonapoptotic (CaspACE"/ 
7-AAD"), early apoptotic (CaspACE+ /7-AAD"), and late apopto-
tic (CaspACB+ /7-AAD+) DCs after 18 hours of culture is shown in 
Figure ID. Low levels of CD200 expression was observed on 
nonapoptotic DCs; however, DCs with activated caspases dis-
played a pronounced increase in CD200 expression. 
We examined CD200 mRNA levels in cultures of DCs undergo-
ing apoptosis to determine whether increased cell surface CD200 
expression correlated with increased mRNA. Splenic C'Dl l c + DCs 
were cultured in medium without growth factors to induce apopto-
sis and total RNA was isolated at various times for both semiquan-
titative and quantitative real-time RT-PCR analysis. Increasing 
levels of CD200 mRNA were observed during the 24-hour culture 
(Figure 2B), peaking at 24 hours when approximately 70% of DCs 
were apoptotic (Figure 2A). CD200 message was detected at time 0 
only when 40 cycles of PCR amplification was used (data not 
shown), correlating with the low levels of CD200 expression on the 
cell surface at time 0 (Figure IB). In quantitative real-time RT-PCR 
assays, we observed more than 8-fold increases in CD200 mRNA 
(relative to 18S rRNA) after 24 hours of culture (Figures 2C and 
4C). Consistent with the up-regulation of CD200 at the transcrip-
tional level during DC apoptosis, we did not detect an intracellular 
store of CD200 protein in freshly isolated (preapoptotic) DCs. (see 
Figure S1 on the Blood website; click the Supplemental Data Sets 
link at the top of the online article.) 
To detennine whether inhibition of apoptosis altered CD200 
expression, DCs were culture in medium supplemented with the 
pan-caspase inhibitor Z-VAD-FMK. Inhibition of DC apoptosis by 
blockage of activated caspases inhibited CD200 expression at all 
time points examined (Figure 4D). 
Increased CD200 expression with apoptosis was not restricted 
to murine DCs. In CI498 leukemia cells, CD200 mRNA and 
protein were initially undetectable; however, there was a pro-
nounced increase in both CD200 mRNA and cell surface protein 
expression as early as 8 hours after y-irradiation, peaking at 48 
hours, when more than 80% of the cells were apoptotic (Figure S2). 
CD200 is a p 5 3 - t a r g e t g e n e 
The tumor suppressor protein p53 has been coined the "master 
regulator" of the apoptotic program because of its pivotal role in many 
of the signaling pathways initiated in apoptotic cells.27 The major 
function of p53 is that of a transcription factor. On being activated in the 
early stages of apoptosis, p53 binds to regulatory elements of various 
genes in a highly sequence-specific manner. p53-mediated gene regula-
tion is thought to bring about many of the distinctive morphologic and 
physiologic characteristics associated with apoptosis. The target consen-
sus sequence for p53-binding (p53 response element or p53RE) has 
been defined,28 and genes that contain this sequence either in the 
promoter region or downstream introns have been shown to be 
transcriptionally activated by p53.29 Translocation and/or accumulation 
in the nucleus are required for p53 to function as a transcription factor30; 
however, p53 activity lias not been characterized in DC apoptosis. To 
detennine whether p53 translocates to the nucleus in apoptotic DCs, we 
examined the intracellular localization of both p53 and caspases by 
immunofiuorescent microscopy. CD1 lc+ DCs cultured for 24 hours in 
complete DMEM were triple-stained with 4',6'diamedmo-2-phcnylin-
dole (DAPI; to detect nuclear DNA), anti-p53 mAb, and CaspACE. 
Cells in which caspases had not been activated (CaspACE-negative) 
consistently showed cytoplasmic or perinuclear staining for p53; 
however; cells with activated caspases (CaspACE positive) consistently 
showed brighter p53 staining that colocalized with DNA (Figure S3). 
Given that CD200 mRNA expression increases and that p53 
translocates to the nucleus with DC apoptosis, we performed a sequence 
analysis of both murine and human CD200 genes to search for 
consensus p53REs. A p53RE consists of at least 2 copies of the sequence 
5'-PuPuPu C(A/T)(T/A)GPyPyPy-3' separated by 0 to 13 base pair 
(bp).28 Some mismatches in this sequence have been shown not to alter 
p53 binding.31 For our analysis, a maximum of 3 variations from this 
proposed consensus sequence was allowed with no more than one error 
in a single decanter if it was located in 1 of the 2 central nucleotides of a 
decanter. The C in position 4 and the G in position 7 were considered as 
invariant positions. These criteria are identical to those used by others to 
Mouse CD200 intron no. 1 
+425 gagcaagccnj cagcttcagt Iggtcttglla j+454 
+2235 
-Q-Exonl 
+2211 +1026 +1049 
Human CD200 intron no. 1 
Figure 3. The genes for both human and murine CD200 contain 
p53REs. Intron no. 1 of murine CD200 has 4 p53REs, and intron no. 1 of 
human CD200 has 2 p53REs. 'Variations from the consensus p53RE 
sequence. +1 represents the Initiation codon. 
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discover the p53REs in the Fas gene.32 We found 4 putative p53REs in 
the first intron of murine CD200 and 2 putative p53REs found in the first 
intron of human CD200 (Figure 3). Of note is the relatively conserved 
location of the second p53RE in mouse intron 1 with the first p53RE in 
human intron 1 from the initiation codon. We tested the ability of the 2 
p53REs contained in the first intron of human CD200 to act as 
cw-enhancer elements in p53-mediated gene expression in vitro. The 
25-bp sequence from 1028 to 1053 (p53RE no. 1) and the 33-bp 
sequence from 1715 to 1748 (p53RE no. 2) encompassing the first and 
second putative p53REs, respectively (Figure 3), were cloned into a 
luciferase reporter vector. A randomly chosen nucleotide sequence from 
the first intron of human CD200 also was cloned as a negative control. 
Each of these vectors was independently cotransfected into NCI-H1299 
cells (which lack functional p53) with or without the pFC-p53 plasmid 
that constitutively expresses wild-type human p53. Increases in lucif-
erase activity after cotransfection are indicative of functional p53REs 
capable of enhancing p53-mediated gene expression. In all experiments, 
no increase in luciferase activity was observed when pFC-p53 was 
cotransfected with control vector; however, cotransfection with vector 
containing either the first or second putative p53REs (p53RE no. 1 or 
p53RE no. 2) produced approximately 50- and 300-fold increases in 
luciferase activity, respectively (Figure 4A). 
To determine if p53 was responsible for increasing expression of 
CD200 during DC apoptosis, we analyzed CD200 expression on 
cultured CDl l c + DCs isolated from the spleens of p53 _ / _ and healthy 
(WT) C57BL/6 mice. DCs were cultured in complete DMEM and 
stained at various times with CaspACE or Annexin V-FITC and 
anti-CD200 mAb in the presence of 7-AAD. DCs from p53~'~ mice 
showed slower kinetics and decreased overall expression of CD200 as 
compared with WT controls (Figure 4B). At 8 hours, the percentage of 
p53 ~ h DCs that stained positive for CD200 was approximately half that 
of WT DCs (22% versus 41%). Furthermore, the overall level of CD200 
expression, as denoted by mean fluorescence intensity (MFI) of 
anti-CD200 staining, was decreased in p53 DCs (MFI = 55 versus 
89 at 8 hours). After 20 hours of culture, DCs from p53~'~ mice had 
comparable percentages of CD200 * cells (49% versus 59%); however, 
the expression levels of CD200 remained reduced (MFI - 86 versus 
134 at 20 hours). Diminished CD200 expression in p53 "'~ DCs also 
was observed after 48 hours of culture (data not shown). To confirm that 
p53 increases transcription of CD200 during DC apoptosis. we per-
formed quantitative RT-PCR on RNA isolated from cultured WT and 
p53~'~ DCs. Decreased levels of CD200 mRNA were observed at all 
time points examined in p53 _ / _ DCs (Figure 4C). In contrast, CD200 
mRNA levels in WT DCs steadily increased with time and apoptosis. 
Delayed expression of CD200 in p53 _ / _ DCs suggests the existence 
of a p53-independent mechanism(s) for apoptosis-driven CD200 expres-
sion. Because caspases appeared to play a role in increasing CD200 
expression (Figure 4D), we sought to determine whether activated 
caspases and p53 act in the same or complementary molecular pathways 
to increase CD200 expression in apoptotic DCs. Splenic CD1 lc+ DCs 
from p53~'~ and WT mice were cultured with and without Z-VAD-
FMK. and CD200 expression was measured over time. Cells were 
Figure 4. p53 and caspases drive CD200 expression 
during DC apoptosis. (A) The first and second putative 
p53REs (p53RE no. 1 and p53RE no. 2) or randomly 
chosen sequence (control) from the first intron of the 
human CD200 gene were cloned into a luciferase expres-
sion vector containing a minimal promoter element. 
NCI-H1299 cells were cotransfected with either of these 
constructs with or without a p53 expression vector (pFC-
p53). Results shown are fold Increases In luciferase 
activity over no pFC-p53 cotransfection for each vector. 
*P < .005 compared with control by Mann-Whitney U 
test. Results are representative of 5 replicate experi-
ments. (B) 00110" DCs were isolated from wild-type 
(WT) and p53~'-C57BL/6 mice and cultured in complete 
DMEM for 48 hours to induce apoptosis. Cells were 
stained with CaspACE and anti-CD200 mAb In the 
presence of 7-AAD at various time points. Shaded and 
unshaded histograms represent staining with antl-CD200 
and Isotype control mAbs, respectively. Cells shown are 
gated on early apoptotic cells (CaspACE"/7AAD"). Re-
sults are representative of 2 replicate experiments. 
(C) Quantitative real-time RT-PCR was performed on 
cultured CD11c" cells derived from either WT or p53 - ' -
mice. Total RNA was normalized to 18S rRNA at each 
time point. Results are representative of 2 experimental 
replicates. (D) CD11c" DCs were cultured in medium for 
48 hours in the presence or absence of 100 pM Z-VAD-
FMK and assayed for CD200 expression. 'P < .05 as 
compared with Z-VAD-FMK treatment. Results are com-
bined data from 3 replicate experiments. (E) DCs from 
WT and p 5 3 m i c e were isolated as described earlier, 
cultured in medium with or without 100 pM Z-VAD-FMK, 
and examined for CD200 expression by flow cytometry. 
Error bars indicate i 1 SD (A, C-D). 
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analyzed for Annexin V binding, 7-AAD uptake, and anti-CD200 
staining (Figure 4E). As previously shown, DCs from p53 - /~ mice had 
diminished levels of CD200 on their surface compared with WT DCs. 
Treatment with Z-VAD-FMK further reduced CD200 expression in 
p53~h DCs at all time points examined (Figure 4E), suggesting that p53 
and caspases may act in different pathways in mediating CD200 
expression during apoptosis. 
CD200 expression with apoptosis alters T-cell activity in vitro 
The autologous MLR is a T-cell-mediated immune response directed 
against autologous APCs. It consists of costimulation-dependent T-cell 
proliferation, primarily by CD4+ T cells, against self-peptides presented 
by self-MHC class II molecules expressed on the surface of DCs.33 
Recently, published studies show that autoreactive T cells in autologous 
MLR cultures recognize and react to self-peptides that have been 
modified by the action of caspases in apoptotic cells and that DCs are 
responsible for processing and presenting these self-antigens to autolo-
gous CD4+ T cells.34'35 Abnonnal autologous MLR responses are often 
observed in patients with autoimmunity, and, thus, this reaction is 
thought to represent a self-recognition mechanism that might be 
important in the establishment and maintenance of peripheral self-
tolerance." Because CD200 expression increases with apoptosis (Figure 
1) and CD200"'" mice have a compromised capacity to maintain 
peripheral tolerance to self-antigens,22 we tested whether CD200 
expression on apoptotic DCs influences T-cell activation in autologous 
MLR cultures. We used apoptotic WT and CD200"'" DCs as stimula-
tors and purified syngeneic (akin to autologous) CD4+ T ceils as 
rcsponders. We characterized the cell surface phenotype of both 
apoptotic CD200+ / + (WT) and apoptotic CD200"'" DCs prior to these 
assays to confirm that DCs from CD200"'" mice differ from WT 
primarily in their level of CD200 expression. CD200 expression was 
minimal on freshly isolated WT DCs but increased after 18 hours of 
culture. CD200 expression was not observed on fresh or cultured 
CD200 DCs. There was little to no difference in CD80, CD86, 
CD40, and MHC II expression between WT and CD200 ; DCs on 
either freshly isolated cells or ceils cultured for 18 hours (Figure 5B). 
This finding is consistent with a previous study showing that BM-
derived DCs from CD200™'~ mice differ from WT only in their level of 
CD200 expression.22 
Prior treatment of DC stimulators with Z-VAD-FMK reduced CD4+ 
T-cell proliferation in autologous MLR cultures by approximately 60% 
(Figure 5A). confirming that T-cell activation in these assays is partially 
dependent on caspase-mediated DC apoptosis. T-cell proliferation was 
significantly increased when CD200+ / + DCs were used as stimulators 
as compared with CD200"' DCs (Figure 5C). This increase in 
proliferation was associated with more than double the amount of IL-2 
production (average of 220% of CD200"'' controls; Figure 5D). In 
contrast, TNFa and IFNy production was significantly reduced by 
- 3 7 % and - 3 8 % , respectively. The average production of IL-5 was 
increased by 277% when CD200+ / + DCs were used as stimulators as 
compared with CD200~'~ controls (Figure 5D). We did not detect IL-4 
in any of these assays. 
CD200 is required for UVB-mediated tolerance in vivo 
To assess the effects of apoptosis-associated CD200 expression on 
immune tolerance in vivo, we used a well-characterized system of 
UVB-induced immunosuppression of contact hypersensitivity. Low-
dose UVB given prior to cutaneous sensitization with hapten 
systemically inhibits the contact hypersensitivity response of 
hapten-specific T ceils.25 UVB-induced apoptosis of epidermal 
DCs (ie, Langerhans cells) is thought to play a role in tolerance 
induction in this model.36 WT and CD200" ' " mice were given 4 
consecutive doses of UVB and sensitized with DNFB on UVB-
irradiatcd abdominal skin 24 hours later. Control mice for each 
group were not treated with UVB prior to sensitization. Five days 
later, nonirradiated cars were challenged with DNFB, and ear 
swelling was measured after both 24 and 48 hours to assess the 
magnitude of hapten-specific contact hypersensitivity. Exposure of 
WT mice to UVB prior to hapten sensitization significantly reduced 
contact hypersensitivity to DNFB when compared with WT mice 
that were not exposed to UVB (Figure 6). In contrast, CD200"'"" 
mice were resistant to UVB-induced immunosuppression. When 
B 
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Figure 5. CD200 expression on apoptot ic DCs results 
In Increased T-cell proliferation and diminished secre-
t ion of proinf lammatory cytokines in caspase-depen-
dent autologous MLR cultures. (A) WT CD11c+ DCs 
were cultured in complete DMEM with or without 200 pM 
Z-VAD-FMK for 24 hours, washed thoroughly, and then 
used as stimulators in autologous MLR cultures with 
purified CD4+ T cells from C57BL/6 mice as responders. 
*P < .05 versus medium control. (B) Cell surface protein 
expression on wild-type (WT) and CD200-deficient 
(CD200"'-) DCs. CD11c+ DCs were cultured in complete 
DMEM for 24 hours to induce apoptosis and stained with 
specific antibodies (shaded histograms) to detect cell 
surface protein expression by flow cytometry. Cells were 
more than 97% CD11c", and approximately 70% were 
apoptotic by Annexin V staining. AGmean represents the 
change in MFI from isotype-matched controls (open 
histograms). (C) CD11C DCs were isolated from wild-
type C57BL/6 (H-2"; CD200" + ) and CD200-dericlent 
(H-2b; CD200"'") mice and cultured In complete DMEM 
for 24 hours to induce apoptosis. Stimulators were more 
than 97% CD11c+, and approximately 70% were apopto-
tic by Annexin V staining at the time responders were 
added. Proliferation was measured at 72 hours by [3H]-
thymldine incorporation. Results are representative of 4 
replicate experiments. ' P < .05 versus WT. (D) Cytokine 
levels were measured from supernatants at 72 hours by 
cytometric bead array. Results are the average of 4 
replicate experiments. 'Statistically significant from 
CD200"' (P < .05) by Student I test. Error bars indicate 
± 1 SD(A, C-D). 
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Figure 6. CD200 is required for UVB-mediated suppression of contact hypersen-
sitivity. Wild-type (WT) or CD200-deficient (CD200"'") mice were either exposed 
(+ UVB) or not exposed to UVB prior to hapten sensitization and challenge. Ear 
thickness was measured at both 24 {not shown) and 48 hours. 'Significantly different 
from aii other groups (P < .01) by Student t test. Results shown are representative 
from 2 replicate experiments. Error bars indicate ± 1 SD. 
CD200" '" mice were exposed to UVB prior to hapten sensitization, 
contact hypersensitivity was not reduced (Figure 6). In a replicate 
experiment, ear swelling was significantly increased (P < .04) in 
CD200 mice that had received UVB when compared with 
CD200" nonirradiated controls (data not shown). Thus, CD200 is 
required for UVB-mediated tolerance in this contact hypersensitiv-
ity model. 
Discussion 
Here, we show that expression of CD200 increases with DC apoptosis 
and suggest that CD200 plays a role in the induction of apoptosis-
associated immune tolerance. The genes for both murine and human 
CD200 contain p53REs that drive p53-mediated gene expression, and 
expression of CD200 during DC apoptosis was partially dependent on 
both p53 and activated caspases. Apoptotic DCs that expressed CD200 
altered T-cell proliferation and cytokine production in autologous MLR 
cultures in vitro and CD200 was required for induction of UVB-
mediated immune tolerance to hapten in vivo. 
Steinman et al6 propose that phagocytosis of apoptotic cells in the 
absence of inflammation (ie, steady state) down-regulates APC activa-
tion and that this process plays a central role in the establishment and 
maintenance of peripheral self-tolerance. These researchers further 
speculate that apoptotic DCs may be the true mediators of tolerance. 
Although we provide no direct evidence that apoptotic CD200+ DCs 
mediate tolerance in vivo, we suggest an important role for CD200 in 
tolerance induction by apoptotic DCs on the basis of our data, showing 
that (1) DCs increase CD200 expression on undergoing apoptosis 
(Figure 1), (2) CD200 expression on apoptotic DCs skews the response 
of autologous T cells to decrease secretion of proinflammatory cytokines 
in vitro (Figure 5C), and (3) CD200 signaling is required for UVB-
mediated tolerance in vivo (Figure 6). Others have shown that induction 
of apoptosis36"38 and alterations in Langerhans cell function3''"41 are 
responsible for UVB-mediated tolerance. 
A direct association between CD200 and apoptosis has not been 
reported in earlier studies that examined both CD200 tissue 
expression and CD200 function. However, CD200 expression is 
highest on thymocytes and migrating neurons.15 Both the thymus 
and the developing nervous system are intense areas of apoptosis. 
In the ovaries, another tissue with intense apoptosis, CD200 is 
expressed almost exclusively on structures that do not develop 
further, such as the granulosa of degenerating antral follicles and 
third-generation corpora lutea.42 Furthermore, CD200 expression 
on trophoblast tissue has been shown to play a role in tolerance 
induction at the maternal-fetal interface.43 Trophoblast tissue is 
highly apoptotic, and the mechanism of maternal-fetal tolerance is 
linked to apoptosis.44 Thus, CD200 may be constitutively ex-
pressed on some tissues and induced with apoptosis in others. 
In some cases, studies on the functional activity of CD200 also 
can be linked to apoptosis. Increased allograft acceptance after 
immunization of mice with allogeneic cells injectcd into the portal 
vein has been attributed to increased CD200 expression on hepatic 
DCs.18 Tolerance induction by portal vein immunization has been 
reported to be due to retention and accumulation of tolerogenic 
apoptotic cells in liver sinusoids.45 A small, slow sedimenting 
population of BM-derived CD200+ DCs has been reported to 
inhibit typc-1 and to stimulate type-2 cytokine production.21 '46 
Although the apoptotic status of the CD2001 DCs was not reported 
in these studies, their small size is characteristic of cells undergoing 
apoptosis (similar to CD200+ cells shown in Figure IB). 
Genes regulated by p53 have been shown to be involved in the 
processes of apoptosis, cell growth, DNA repair, and angiogen-
esis,29 but data are limited showing that p53 regulates genes 
involved in immune modulation. We found that p53 associates with 
DNA in apoptotic DCs (Figure S3) and that CD200 mRNA 
expression increases with DC apoptosis (Figure 2), suggesting to us 
that CD200 might be a p53-target gene. By using the same 
approach that was used to find p53REs within the Fas gene,32 we 
identified 4 putative p53REs in the first intron of murine CD200 
and 2 putative p53REs in the first intron of human CD200 (Figure 
3). As in that report, we did not find putative p53REs upstream of 
the transcription initiation site in the proposed promoter region. 
Interestingly, the second p53RE in the mouse CD200 gene is within 
2 nucleotide base pairs from the first p53RE in the human CD200 
gene relative to the initiation codon (Figure 3), suggesting the 
possibility that this is an evolutionarily conserved enhancer ele-
ment. p53REs cloned from the human CD200 gene were functional 
in a p53-luciferase reporter system (Figure 4A), and CD200 
expression was diminished in DCs from p53~ ;~ mice (Figure 4B). 
confirming that CD200 is a bona fide p53-target gene. 
Multiple lines of evidence suggest that CD200-CD200R is an 
immunomodulatory pathway leading to the suppression of T-cell-
mediated immune responses as well as down-regulation of innate 
immunity.15'22'47 The data presented here suggest that CD200 
facilitates the induction of tolerance to autoantigen in the contcxt of 
apoptosis. Presumably, this occurs through ligation of CD200R. 
Whether CD200 interacts directly with T cells in a physiologically 
relevant manner or indirectly through CD200R+ APCs is not yet 
clear. In a recent report, Wright et al16 used CD200R-specific PC.R 
primers and staining with new anti-CD200R mAbs to show that T 
cells express the receptor for CD200. We also found that murine T 
cells expressed CD200R mRNA and that they weakly bind soluble 
CD200, resulting in a novel cytokine expression profile in T-cell 
costimulatory assays in vitro (M.D.R., manuscript submitted, 
September 2003). 
In the apoptosis-linked tolerance induction model proposed by 
Steinman et al,6 tissue-resident DCs in steady state are not stimulated 
and remain immature during migration to afferent lymph nodes. These 
short-lived migratory DCs subsequently undergo apoptosis in T-cell 
areas of the lymph node where longer-lived lymph node-resident DCs 
process them and their contents. Inaba et al13 propose that when 
self-antigens from noninflamed tissues (eg, during natural cell 
turnover) arc brought to the T-cell areas by peripheral DCs, they arc 
subsequently processed by lymph node-resident DCs in a regula-
tory and tolerogenic fashion. 
Collectively, our findings, together with the finding that 
CD200"'"" mice have increased numbers of constitutively activated 
WT WTTUVB tBOO* CD2flW-+ UVB 
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APCs and are prone to induction of autoimmune disease,22 suggest 
that CD200 may play a role in apoptosis-linkcd peripheral toler-
ance to self-antigens. The mechanisms involved remain to be 
determined. In the context of natural cell turnover, induccd as well 
as constitutive expression of CD200 may contribute to the mainte-
nance of a noninflammatory milieu because CD200 plays a role in 
the homeostatic control of innate immune responses through A c k n o w l e d g m e n t 
regulation of macrophages and granulocytes.15'47 With identifica-
tion of CD200-receptor expression on murine and human T cells, 
direct interaction between CD200* DCs and T cells is an alterna-
tive mechanism. Failure to control peripheral immune response to 
self-proteins modified during natural cell death is a potential trigger 
for autoimmune disease." CD200-CD200R interaction may be an 
important pathway in such a setting. 
We thank Dr Jonathan Sedgwick, DNAX (Palo Alto, CA) for the 
generous gift of CD200-deficient mice. 
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